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ABSTRACT OF THE DISSERTATION
DUAL ROLE OF RIN1 IN CANCER CELL BEHAVIOR:
IS CORTACTIN A NEW RIN1-INTERACTING PARTNER?
by
Wei Zhang
Florida International University, 2019
Miami, Florida
Professor Manuel Alejandro Barbieri, Major Professor
Growth factors play an essential role in abnormalities in both intracellular trafficking
and signal transduction pathways responsible in normal and cancer cells. Growth factors,
such as epidermal growth factor, represent a main course on the activation of mitogenic
signal that contribute to the mitogen activated protein kinase (MAPK) pathway affecting
cell proliferation, which is driven by Ras GTPases. However, it also induces a profound
morphological change by reorganization actin and other cytoskeleton proteins, which are
driven by other GTPases (i.e., Rho and Rac).
The key cytosolic protein Ras interference 1 (Rin1) regulates both membrane
trafficking and signaling pathways through the Rin1:Vps9, which activates Rab5, and Rin1:
RA, which interacts with Ras, respectively. In addition, Rin1 proline rich domain (Rin1:
PR) may also help to orchestrate this complex regulation by interacting with Cortactin,
which is a key molecule in actin organization at the plasma membrane via Cortactin:SH3
domain. Thus, it is possible connection between Rin1, an effector of the active form of Ras
as well as an activator of Rab5, and subsequent interaction with Cortactin is of particular
interest as cortactin is frequently overexpressed in cancers.
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In the present study, Rin1 works with a dual action: First, it sequesters cortactin and
thus, it blocks the cellular migration and invasion driven by cortactin. Second, interaction
of RIN1 with Ras in the GTP-bound form decreased serine phosphorylation of Cortactin.
The inhibitory effect of RIN1 on the phosphorylation of Cortactin may be due since the
interaction of Ras, which blocks both Erk and Akt activities upon EGF stimulation.
In addition, Rin1 inhibits cell proliferation in cancer cells through Ras-Raf-Erk and
PI3K-AKT signaling cascades by selectively affecting FOXO1 and c-Myc. The selective
inhibitory effect seems to be observed on breast cancer cells but not in other cancer cell
lines (human melanoma and human glioblastoma cells). In summary, the current research
discovered a new activity for RIN1 in metastatic breast cancer cell lines. It interacts with
Cortactin, and also decreases Cortactin function, which as an enhancer of tumorigenic
activity. Thus, Rin1 may play a novel tumor suppressor role in modulating signaling
through the Ras/MAPK and Ras/Akt pathways upon EGF stimulation.
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CHAPTER 1
INTRODUCTION
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1.1 Introduction
Cancer is a disease of profound import for human health, as it is the most important
causes of mortality worldwide (Liu et al., 2016). From a molecular vantage point, cancer
may result from genetic mutations and epigenetic changes which alter the regulation of
many hallmarks of cancer cells, including proliferation, migration and invasion (Sever &
Brugge, 2015). Migration is one of the natural mechanisms of cell behavior and is usually
related to cell survival (Justus et al., 2014; Yang et al., 2017). However, in cancer cells,
uncontrolled migration can lead to cancer cell invasion and metastasis, which in turn, may
cause undesirable effects on the whole organism (Mutch et al., 2014). Migration and
invasion are crucial components involved in cell invasion and metastasis. Metastasis is
highly complex and is also regulated by several growth factors as well as specific
intracellular signal pathways (Bozzuto et al., 2010; Pellinen & Ivaska, 2006). The
mechanism of signaling cascades events in cancer cells are modulated by two opposing
functional proteins, suppressors and oncogenes (Milstein et al., 2007).

1.2 Characteristics of cancer
Many characteristics of cancer performance were elucidated such as tissue invasion
and metastasis, gained angiogenesis, unlimited potential replicative, escaping apoptosis,
lower reaction to anti-growth signals and self-sufficiency in growth factor induced
pathways. Although the six stages of normal cell transformation into cancer cells are
described as different, each phase is complementary and they work together (Hanahan &
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Weinberg, 2000). Some important factors including invasion, migration, proliferation and
growth factor induced signaling transduction pathways were studied and discussed in the
project.

1.2.1 Cancer cell proliferation
Proliferation plays a vital role on tumorigenesis and development (Farber, 1995). This
process is highly regulated by the modified protein expression and activity associated with
the cell cycle. Additionally, cell growth is enhanced by uninterrupted activation the cell
signaling transduction pathways. The early stages of tumor development are associated
with the formation of fibroblast responses and hypoxic conditions, which contribute to the
survival and proliferation of cancer stem cells (Feitelson et al., 2015).

1.2.2 Cancer cell migration and invasion
Migration is the one of the natural physical steps in cell development and it is usually
benign to regular cell growth. However in cancer cells, migration can lead to cancer cell
metastasis and cause harmful effects on organisms (Mutch et al., 2014). Cancer invasion
and migration can change the location of cancer cells in tissues and drive cancer cells to
distant tissues and organs (Friedl & Wolf, 2003). Cell migration is the step which is
triggered by the integrin-molecular binding with specific cell surface receptor (Pellinen &
Ivaska, 2006). These include epidermal growth factor (EGF) binding with epidermal
growth factor receptor (EGFR), insulin growth factor 1 (IGF-1) binding with insulin
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growth factor receptor 1(IGF-1R) (Walsh & Damjanovski, 2011) and fibroblast growth
factor (FGF) binding with fibroblast growth factor receptor (FGFR). These strong chemical
inducers promote invasion and migration (Knuchel et al., 2015). Cancer cells exhibit
several types of migration which are classified as mesenchymal single cell migration,
amoeboid single cell migration, collective cell migration and scaffold cell-dependent cell
migration (Kawauchi, 2012) (Figure1.1).

Figure 1.1. Classification of cell migration types. Orange dots: cell-ECM adhesions;
Red rectangles: cell-cell adhesions; Black bars: ECMs. (Kawauchi, 2012)

1.2.2.1 Single cell migration
Most studies show that individual tumor cells become motile to escape form primary
tumors (Friedl & Wolf, 2003). The loss of correlation with neighbor cells resulted in the
absence of cell-to-cell adhesion (Friedl et al., 2012). The lack of cell to cell adhesion can
be classified into two different types: amoeboid single cells migration and mesenchymal
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single cell migration (Ridley et al., 2003). These classifications are defined by cell-matrix
adhesion, the structure of the cytoskeleton and the capacity to remodel the extracellular
matrix (ECM) (Clark & Vignjevic, 2015).

1.2.2.2 Mesenchymal single cell migration
Mesenchymal cells are solid cells which show a strong power to migrate. The progress
of migration is listed below: First, it forms the protrusion at the leading edge which is
driven by actin filament and its partners. Second, integrin is released and interacts with the
ECM and clusters in the plasma membrane and interacts with Rac and Rho (Parri &
Chiarugi, 2010). Third, the large amount of ECM-degrading enzymes such as matrix
metalloproteinases (MMP) are up-regulated and move through the matrix using
degradation enzymes (Wolf et al., 2003). Next, the cells are contracted as a result of the
action of actomyosin which is regulated by Rho. Finally, the contractile force driven
actomyosin empower movement. Furthermore, it has been shown that IGF-1 can induce
the invasive ability in breast cancer cells (Walsh & Damjanovski, 2011).

1.2.2.3 Amoeboid single cell migration:
Amoeboid single cell migration is not the common way for cancer cell invasion and
migration to proceed. Mesenchymal migration is the more common process than the
amoeboid single cell migration (Friedl & Wolf, 2003). Mesenchymal migration has low
affinity with the ECM and is not necessarily dependent on the ECM-degrading enzymes.
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In other words, even though it inhibits the function of integrin, the movement of the
amoeboid cannot be prevented (Friedl, 2004). During amoeboid migration, the shape of the
cell is the round cell body and their protrusive activity is dramatically different from
mesenchymal migration (Clark & Vignjevic, 2015).

1.2.2.4 Collective cell migration:
Collective means the migration contains cell-cell and cell-ECM adhesions. It exits in
multiple cancer cell types such as breast cancer (Cheung et al., 2013), melanoma and
epithelial prostate cancer and so on. Contrary to single cell migration which occurs with
the loss of adherent junctions, the maintenance of adherent connections plays a vital role
during movement. However, the regulatory pathway depends on collective migration and
its clinical value has not yet been clarified (Friedl & Wolf, 2008; Wolf et al., 2007).

1.2.2.5 Scaffold cell-dependent cell migration
Scaffold cell-dependent cell migration progress highly depends on cell-cell adhesion
whereas cell-ECM adhesion is less or not required. The typical example is neural cell
migration. Immature neural cells migrate far distances through radial glial fibers and Ncadherin is essential for the binding with radial glial fibers when the neural cells are
undergoing locomotion. Moreover, N-cadherin is regulated by the Rab GTPase endocytic
pathway (Kawauchi et al., 2010; Nishimura et al., 2010).
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1.2.3 Cortactin in cancer cell migration
Cortactin is an actin nucleation promoting factor that regulates cell migration and
invasion and is actively involved in adaptation of aggressive cancer cells (MacGrath &
Koleske, 2012). Cortactin plays an essential role in tumor progression and with stimulation
of EGFR, and has been involved in regulation of receptor mediated endocytosis (Fantozzi
et al., 2008). It contains an N-terminal acidic region, six and a half 37-amino acid repeats,
a proline-rich region and a SH3 domain at a COOH terminus that mediates the interaction
of numerous proteins (Weed et al., 2000) (Figure 1.2). In the N-terminal acidic (NTA)
region, it can bind and activate the Arp2/3 complex. Furthermore, the repeats region is
significantly interacting with F-actin. For the C-terminus region, the proline rich region
contains serine and tyrosine phosphorylation sites (Weaver, 2008). The cortactin SH3
domain can bind multiple cytoskeletal proteins which can link these proteins to abundant
processes such as endocytosis and cell migration (MacGrath & Koleske, 2012).

Figure 1.2. The structure of cortactin. Cortactin comprises of multiple domains
regulating cellular signaling which includes NTA and F-actin binding domain in the N
terminus, proline rich and SH3 domain in the C terminus.
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Except for the binding with numerous proteins via SH3 domain, multiple posttranslation modifications regulate the responsibility of cortactin as well. Stimulation of
cortactin phosphorylation is regulated by the activation of tyrosine kinase receptor Her2 in
cancer cells (Garcia-Castillo et al., 2009). Additionally, cortactin can be phosphorylated
by Src kinases and involved in downstream signaling (Ren et al., 2009; Vuori & Ruoslahti,
1995). The Src family kinases phosphorylate cortactin on the site of Y421 and Y466 in the
proline rich domain, and Y482 as well (Huang et al., 1998).
Tyrosine phosphorylation of cortactin will initiate recruitment of SH2 protein such as
Nck adaptor1 (NCK1) which links to the interaction with N-WASP and WIP, resulting in
the activation of Arp2/3 (Oser et al., 2010; Tehrani et al., 2007). The finding about the
relationship between tyrosine phosphorylation of cortactin and activation of Arp2/3
supports the observation of tyrosine phosphorylated cortactin inducing lamellipodia
protrusion and cell migration (Kowalski et al., 2005). On the other hand, cortactin is also
be phosphorylated by serione/threonine kinases. Previous studies showed that extracellular
signal-regulated kinase (ERK) phosphorylated cortactin at S405 and S418 residues
(Campbell et al., 1999). Interaction with N-WASP is enhanced by Erk phosphorylation and
leads to the increasement of actin phosphorylation regulated by the Arp2/3 complex
(Martinez-Quiles et al., 2004). Moreover, phosphorylation of tyrosine and serine at the
same time reveals cortactin downstream signals can be integrated form various upstream
signaling cascades (Kelley et al., 2010). Increasement expression level of cortactin has
been shown in numerous different type of cancer cells (Campbell et al., 1996; Xu et al.,
2010; Yamada et al., 2010). The elevated phosphorylation of cortactin is essential to the
cancer cell metastasis and related to the aggressiveness of cancer cells (Li et al., 2001).
8

Overall, cortactin has been shown to be important in cancer cell migration, invasion and
metastasis.
1.2.4 Metastasis
Metastasis is a multifaceted process that allows cancer cells to escape from the primary
tumor and spread to a secondary location. Metastasis always comes with the loss of cellcell attachment, remodeling cell-matrix adhesion and upregulation of ECM-degrading
enzymes. In a number of studies, the process of metastasis has been clarified as consisting
of: 1) Detachment from primary tumor 2) invasion into neighboring tissues 3) circulating
tumor cells 4) adhesion into blood walls, and 5) extravasation and growth at secondary
location. Cell invasion, migration and proliferation is in response to each step in metastasis
(Joyce & Pollard, 2009; Yilmaz & Christofori, 2009). With the development of the
technology to detect the early stage of cancer and advanced therapy, it has already
improved the percentage of cancer patients’ survival. However, the benefits of current
cancer therapies are reaching a plateau. To overcome this situation, the application of the
knowledge derived from metastatic signaling events to clinical treatment is significant
(Wan et al., 2013).

1.3 Growth Factor Signaling in Cancer Cells
Cancer has been defined as a disease characterized by an increase in cell growth,
cellular motility and the acquisition of unlimited survival capacities in mutated cells
(Gutschner & Diederichs, 2012; Lopez-Saez et al., 1998; Porther & Barbieri, 2015).

9

Receptor tyrosine kinases (RTK) contribute to uncontrolled cell proliferation, migration
and survival and are differentially expressed on multiple types of cancer cells (Azuaje et
al., 2015).
Receptor tyrosine kinases are a family of cell surface receptors, which contain EGFR,
insulin growth factor receptor and others (Li & Hristova, 2006). The epidermal growth
factor receptor has a vital effect on cell proliferation, invasion, migration and viability.
Importantly, it is typical in growth factor receptor trafficking (Kong et al., 2007). Insulin
growth factor receptors are universal and multifunctional tyrosine kinase receptors.
Previous studies have pointed out that the IGFR is overexpressed in estrogen receptorpositive cell lines. Overexpression of IGFR has been involved in several types of tumors
such as breast, lung and colon cell carcinoma (Mezi et al., 2012). Receptor tyrosine kinases
act as receptors for multiple functions such as growth factors, hormones, and other
extracellular signaling molecules. Importantly, RTKs mediate two major signaling
pathways which are Ras/Raf/MEK/ERK and PI3K/AKT (Hu et al., 2013), which may
further activate specific and selective signaling molecules that in turn, can affect cell
proliferation, invasion and cell migration (Regad, 2015).

1.3.1 Epithelial growth factor
Epithelial growth factor, which is a single-chain polypeptide, has effects on
proliferation and differentiation of many mammalian tissues (Hauner et al., 1995). It is
known that the enhancement of cell migration and invasion is promoted by EGF (Hebert
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et al., 2009; Tamama et al., 2006). A conserved EGF domain was shared in the EGF family.
All the members of EGF family was similar to many other growth factors like HGF,
originate from membrane-bound precursor proteins. Additionally, all the family members
are bound to the ErbB class of four receptor tyrosine kinases which is also called Her2,
Her2, Her3 and Her4. Additionally, for the ErbB group, each ErbB molecule contains an
extracellular domain that allows ligand binding, a transmembrane portion and an
intracellular protein tyrosine kinase domain, which is similar to other tyrosine kinases
(Zheng et al., 2006).
Mutations, amplification or dysregulation of at least one ErbB family member have
been found in more than 20% of solid tumors with autocrine loops involving epidermal
growth factor-like ligands. For instance, about 50% of gliomas have EGFR gene
amplification (Wong et al., 1987), including a large part of EGFRvIII which is lacking part
of the extracellular domain in EGFR (Jeuken et al., 2009). It is worth pointing out that this
mutant presents continuous phosphorylation of tyrosine and has effects on various down
streaming pathways (Huang et al., 2009). Human epidermal growth factor receptor2 (Her2)
barely causes tumor-causing mutations in tumors (Shigematsu et al., 2005), but in
metastatic breast cancer, 20%-25% the homologous part of chromosome 17 is amplified,
which is related with the poor prognosis (Slamon et al., 1987). Human epidermal growth
factor receptor2 (Her2) has also been overexpressed in ovarian cancer, gastric cancer, and
invasive uterine cancer. In human breast cancers, Her3 is usually expressed together with
Her2, and overexpression of neutrophil regulatory proteins (the natural ligands of Her3 and
Her4) results in an increase in tumorigenicity (Atlas et al., 2003; Krane & Leder, 1996).
Recent studies have shown that the Her4 is mutated in 19% of melanoma patients.
11

Moreover, the increasement of kinase activity and ability of transformation resulted in
seven Her4 mutations (Prickett et al., 2009).

1.3.2 Insulin growth factor
The IGF system comprised of two ligands (IGF-1 and IGF-2), cell surface receptors
including IGF-1R and IGF-2R, six high-affinity IGF binding protein (IGFBP1-6) families,
and IGFBP-degrading enzymes (Arnaldez & Helman, 2012; Bohula et al., 2003). Under
the control of growth hormone, IGF-1 is mainly produced in the liver and relied on the
growth hormone. IGF-1 plays a critical role in the growth of children and plays an anabolic
role in adults. Most of the circulating IGF-1 molecules bind to IGFBP, thereby rarefying
the biological activity of growth factors. The function of IGF-1 is mediated by the binding
of the receptor tyrosine kinases, low affinity of insulin receptors, together with their
heterodimers. Diversely, IGF-2 not only can bind with IGF-1 receptor but also to the IGF2R/mannose 6-phosphate receptor. Interestingly, IGF-2 is the unique ligand binding to the
IGF-2R/mannose 6-phosphate receptor (Witsch et al., 2010).
It is currently believed that although the IGF-1 system may not produce forceful
oncogenic signals, its integrity is critical for the survival of transformed cells standing on
the recent research(Sell et al., 1994). Notably, in many different types of tumors, IGF
system receptors are expressed IGF-1R produces a powerful anti-apoptotic signal by
activating PI3/Akt pathway. The amplification for the IGF-1R locus in the breast cancer
and melanoma has been discovered while high IGF levels are linked to the high risk of

12

breast cancer (Almeida et al., 1994; Hankinson et al., 1998). Moreover, the level of plasma
IGF1 has strongly positive correlation with the risk of the prostate cancer (Chan et al.,
1998). For the IGF-2, it is like to the IGF-1 which participates in the tumor development
supporting by the animal model (Christofori et al., 1995).

1.4 Endocytosis and Cancer
Recent studies have shown that endocytosis plays an important role in the cancer cell
invasion, migration, metastasis and cell signaling transduction (Mellman & Yarden, 2013).
The extracellular substances were transported into the cells accompanied with plasma
membrane deformation movement. Three different types of endocytosis can be divided
relying on the mechanism of entry into cells and size of the invading substances:
phagocytosis, pinocytosis and receptor mediated endocytosis (Besterman & Low, 1983).
In the highly ruffled part of the cell membrane, pinocytosis always occurs. Pinocytosis
internalizes particles smaller than 100 nanometers into cells whereas phagocytosis refers
to the invagination of particles over 250nm (Besterman & Low, 1983). Recent studies show
that the small GTPases of Rab proteins have a critical function in cancer cells as regulating
the process of the endocytosis and resulting in the enhancement of cancer cell migration
and invasion (Tzeng & Wang, 2016).
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1.4.1 Receptor mediated endocytosis
Receptor-mediated endocytosis is the process by which cells rely on receptor
specificity on the cell surface to take up extracellular proteins or other compounds. The
detailed are listed as below: The receptor on the cell surface is highly specific and combines
with the corresponding ligand to form a complex, and then the part of the plasma membrane
is recessed to form a small pit, after that, the pit and the plasma membrane are separated to
form a vesicle leading to extracellular substances taken into the cells. The vesicles also
called endosomes, and following endosome trafficking requires abundant proteins such as
the dynamin GTPases, AP2, and the Rab proteins. After being introduced into the cells by
the vesicles, the outer coat is removed and combined with the small vesicles of the
endosomes to form a large endosome, the content of which is acidic, and the receptor is
separated from the ligand. In this step, Rab protein especially Rab5, plays an important role
in the early endosome fusion and formation. Part of the membrane structure with
internalized receptors falls off, and then fuses with the plasma membrane, finally returns
to the plasma membrane to complete the recycling of the receptor (Stahl & Schwartz, 1986).
Receptor tyrosine kinases signaling is highly regulated by the endocytosis process.
Activated RTK by growth factor participates in various cellular signaling (Goh & Sorkin,
2013). The typical example of the receptors is like EGFR, IR, FGFR, and platelet-derived
growth factor receptor (PDGFR). Overall, Receptor mediated endocytosis results in the
multiple cell signaling activation leading to the cell proliferation, migration, differential
and apoptosis (Dobrowolski & De Robertis, 2011).
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1.4.2 Rab5 and endocytosis
The signal cascades activated by RTK involve different proteins. Numerous proteins
are recruited and play a key role in the activation signaling cascade after activation of
receptors. Several studies have indicated that small GTPases, like Rab and RAS proteins
play important roles in receptor-mediated endocytosis, vesicle trafficking, actin
remodeling of the cytoskeleton and signal transduction (Lundquist, 2006; Wennerberg et
al., 2005). These specific proteins have two forms, an active form of GTP binding and an
inactive form that binds to GDP. Among them, guanine nucleotide exchange factors (GEFs)
act like molecular switches, can activate these small GTPases, thereby facilitating the
exchange from GDP to GTP. In contrast, GTPase activating protein (GAP) promotes the
hydrolysis of GTP, rendering it inactive (Bryan & D'Amore, 2007).
Receptor tyrosine kinase signaling regulates several intracellular molecules that
activate numerous GTPases, including Ras and Rab5 proteins. Most research has found
that Rab5 plays an important regulatory role in endocytosis and early endosomal fusion
(Tall et al., 2001) (Nielsen et al., 1999). Similar to other GTPases, Rab5 has limited
inherent GTPase activity and relies on other enzymes for GTP hydrolyzation like GAPS,
thereby downregulating its activity. Tre-2 / Bub2 / Cdc16 (TBC) catalytic domain are
shared in the enzymes and the function is hydrolyzing GTP. For example, the most
common Rab5 GAP proteins are RabGap5 (Haas et al., 2005), RN-tre (Lanzetti et al., 2007)
and TBC-2 (Liu & Grant, 2015). On the other hand, for Rab5 GEF, they can activate Rab5
by converting the GDP stage to GTP stage. Their common feature is to share a highly
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conserved Vps9 (cavitating protein sorting 9) domain, such as Rabex-5 (Mattera et al.,
2006), RIN1 (Tall et al., 2001) and Rap6 (Hunker et al., 2006).
Ras is activated by SOS, a specific GEF (Boriack-Sjodin et al., 1998), and Rab5 is
activated by RIN1 (Tall et al., 2001) upon EGF stimulation. Once activated, Ras is able to
interact with several effectors with a variety of signaling effects. If RAF-1 is involved, it
will play an important role in upregulation of cellular proliferation via mitogen-activated
protein kinases (McCubrey et al., 2007). Alternatively, if RIN1 is associated with Ras, then
downregulation of cellular proliferation could be affected. However, Rab5 in the GTPbound form showed a positive effect on RTK internalization that in turn resulted in
decreased modulation of RTK signaling (Barbieri et al., 1998; Hu et al., 2013; Tall et al.,
2001). Thus, RIN1, Rab5 and Ras molecules appear to comprise a key network in
regulating several intracellular events leading to cell proliferation, migration and invasion,
critical hallmarks for cancer cells.

1.5 The role of RIN1 in cancer cells
Ras interference 1(RIN1), has been defined as a Ras effector protein and has been noted
in the cancer research literature. RIN1 is a multifunctional protein, which contains SH2
and proline-rich (PR) domains in N-terminal, and VPS9 and RA domains in the C-terminal
(Bliss et al., 2006). Numerous lines of evidence lend credence to the hypothesis that RIN1
could be a critical intracellular factor linking RTK activation with cell survival. First, RIN1
has been shown to possess the ability to interact with RTK such as EGFR and IR via the
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SH2 domain (Barbieri et al., 2003). Second, it has been demonstrated that the PR domain
in RIN1 can bind with SH3 binding regions. Previous studies show that it can interact with
proteins such as signal-transducing adaptor molecule (STAM) (Kong et al., 2007) and that
it also can bind to the c-Abl SH3 domain (Hu et al., 2005). Third, Rab5 interacts with RIN1
through VPS9 domain which promote Rab5 activation (Tall et al., 2001). Finally, the RA
domain can selectively interact with Ras proteins in the GTP-bound form, thus competing
with RAf-1 proteins (Han et al., 1997) (Figure 1.3 & Figure1.4).

RIN1

SH2

PRD

Vps9

RA
783

1
67-153

477-616

624-709

Figure 1.3. Domains present in RIN1 proteins. The N-terminus contains the SH2 (Src
Homology 2) and PR (proline rich) domains. The Vps9 (vacuolar protein sorting 9) and
the RA (Ras association) domains are located at the C-terminus.
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A)

B)

C)

D)

Figure1.4. 3D Crystal structure presents RIN1 individual domains : A):SH2 domain
(PID:1JYU) (Nioche et al., 2002), B) Proline rich domain (PID:2MPL) (Clifton et al.,
2014), C) RA domain (PID: 5KHQ) (Gingras et al., 2016) D) VPS9 domain (PID:1TXU)
(Delprato et al., 2004)

The RIN family is composed of three members named RIN1, RIN2, and RIN3. They
have several domains in common (i.e., SH2, PR, Vps9 and RA domains). Interestingly, the
difference among those three proteins are the region corresponding to the PR domain. RIN1
has one PR domain, whereas RIN2 has two, and RIN3 has three, respectively.
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1.5.1 RIN1 in Breast Cancer
Breast cancer is a general tumor existing in women, and the incidence rate is increasing
in recent years (Dai et al., 2016). Most of the research focusing on breast cancer cells has
already been done, but there are some issues that still need to be resolved (Dai et al., 2016;
Ryu et al., 2016). New suppressors need to be found and understanding the mechanism of
reoccurring breast tumors needs more in depth investigation.
The most common tumor suppressor discovered in breast tumors are P53 and PTEN
(Kurose et al., 2002) and other low frequency reported suppressors been described in
several paper such as BRCA1 and BRCA2 ( Baselga and Norton 2002). Milstein et al.
found that RIN1was a breast tumor suppressor gene in 2007 (Milstein et al., 2007). It has
been tested in several breast cancer cell lines, and the expression of RIN1 showed a
significant decrease compared with human mammary epithelial cells. Additionally, the
mRNA levels of RIN1 were consistent with the protein expression results. The mechanism
of RIN1 as a tumor suppressor is divided into several parts: 1) the expression of SNAI1
(snail family transcriptional repressor 1) is higher than the human mammary epithelial cells
and SNAI1 is a repressor of RIN1 expression. The transcriptional repressor SNAI1 has the
ability to silence the CDH1 (E-cadherin) which mediates the cell-cell junctions involved
in epithelial–mesenchymal transitions and plays vital role in cell invasion and migration
(Batlle et al., 2000; Cano et al., 2000). 2) Ras interference 1(RIN1) silencing in breast
cancer sometimes happened because of DNA methylation. DNA methylation typically
occurs in CPG Island accompanied by inhibition DNA transcription (Baylin & Ohm, 2006).
3) Overexpression of RIN1 changes the tumor phenotype and leads to decreased growth
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rate of tumor. 4) In breast cancer invasion, RIN1 is a negative regulator. RIN1QM, a mutant
loss the function to bind with ABL but still active Rab5 shows increasing the invasion
growth (Balaji & Colicelli, 2013). These results illustrate that RIN1 mediated tumor
suppression proceeds by activating the ABL-RIN1 pathway that has already been found to
inhibit cell invasion and migration (Hu et al., 2005).

1.5.2 RIN1 in Lung cancer
Lung cancer is the major cause of cancer death and non-small cell lung cancer consists
of 80-85% total lung malignant tumors. Tomshine et al. discovered that overexpression
RIN1 promote cell proliferation in non-small cell lung adenocarcinoma cell lines.
(Tomshine et al., 2009) The mechanism they elucidated RIN1 enhance cell proliferation
mediating EGFR signaling pathway which is regulated by internalization and endocytic
trafficking. Wang et al. reported the relationship between RIN1 overexpression and the rate
of patients’ survival. The results have shown that RIN1 up regulation linked with poor
prognosis of NSCLC patients (Wang et al., 2012).

1.5.3 RIN1 in Melanoma
Melanoma, also called malignant melanoma, develops from pigment-containing cells
and has high invasion ability. There has been a rapid increase of incidence rates over the
past few years (de Braud et al., 2003). Ping Fang et al. found that the RIN1 played oncogene
correlated with poor prognosis in melanoma (Fang et al., 2012).Fang et al. found half of
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melanoma tumor samples overexpressed RIN1 whereas RIN1 had weak expression in
melanocytic naevi. Furthermore, they discovered RIN1 expression was significantly
augmented in the cutaneous melanomas with tumor thickness. In clinical studies, they
found patient survival is highly correlated with RIN1 expression. Patients who have RIN1negative melanoma showed high survival than the positive melanoma. On a molecular level,
depletion of RIN1 inhibits cell proliferation and induces apoptosis in melanoma cells.
Overall, they concluded that RIN1 is related with poor survival of patients and is a
candidate biomarker for drug targets.

1.5.4 RIN1 in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) represents the most widely known cancer type in liver.
Hepatocellular carcinoma is the fifth malignancy worldwide of cancer. Meanwhile it is the
third leading cause of cancer death with elevating incidence (Scartozzi et al., 2012). He et
al. detected that RIN1 inhibited cell migration and is a tumor suppressor in HCC (He et al.,
2013). First, in protein levels, they found RIN1 expression is lower in multiple samples
than the non-cancerous counterparts. In clinical studies, patients with high RIN1
expression's survival frequency is higher than the patients with low RIN1 expression.
Additionally, overexpression of RIN1 in HCC cell lines inhibit cell invasion. The likely
mechanism is RIN1 interacting with ABL which stimulates the RIN1-ABL pathway which
can regulate cancer invasion. Additionally, results show that secretion of MMP function to
decrease the occurrence of epithelial-to-mesenchymal transitions (EMT) leading to cell
invasion and migration has significantly decrease in HepG2 cells (Zhao et al., 2011).
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1.5.5 RIN1 in gastric cancer, bladder urothelial carcinoma and colorectal cancer
Gastric cancer is the second common cancer in the world and a high percentage of
stomach tumors are malignant. Yu et al. discovered that RIN1 plays an oncogenic function
in gastric adenocarcinoma (Yu et al., 2012). Both protein and mRNA levels showed that
RIN1 was overexpressed in gastric adenocarcinoma tumor tissues. Moreover, 5 years over
expression RIN1 adenocarcinoma patient’s rate of survival are definitely lower than
patients who have the low expression of RIN1. Bladder cancer is the fourth most common
cancer in men and has a poor prognosis when the tumors invade the muscular uroepithelial
layer. Shan et al. found that overexpression of RIN1 results in poor prognosis (Shan et al.,
2012). Compared with adjacent normal appearing tissues, urothelial carcinoma shows up
regulation of mRNA levels and over expression in protein levels. Senda et al. investigated
the relationship between RIN1 and colorectal cancer (Senda et al., 2007). They concluded
that RIN1 serves as the signal transduction system behind the malignancy of colorectal
cancer. Both gene expression and protein expression levels show that RIN1 is
overexpressed in colorectal cancer cell lines. In cytoplasm, RIN1 is highly expressed and
binding with 14-3-3 protein whereas there is no expression in cell membrane. Augmented
RIN1 gene was associated with a lower survival rate which predicts that RIN1
overexpression leads to the malignant potential of colorectal cancer.
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Cancer cell type

RIN1 function

Breast cancer

Tumor suppressor, inhibit invasion
(Milstein et al., 2007)

Non-small cell lung cancer

Overexpression with poor prognosis,
promote cell proliferation (Wang et al.,
2012)

Melanoma

Oncogenic protein, increase the rate of
invasion (Fang et al., 2012)

hepatocellular carcinoma

Tumor suppressor, inhibit invasion,
induce apoptosis (He et al., 2013; Zhao
et al., 2011)

gastric cancer

Overexpression with poor prognosis (Yu
et al., 2012)

bladder urothelial carcinoma

Overexpression with poor prognosis
(Shan et al., 2012)

colorectal cancer

Overexpression with poor prognosis
(Senda et al., 2007)

Table 1.1. RIN1 function in different types of cancer
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1.6 Specific aims
Several studies have shown that RIN1 may act as a tumor suppressor in breast cancer
cells, while in the lung cancer cells may act as a non-tumor suppressor. Interestingly,
overexpression of RIN1 has been described as associated with a poor prognosis in nonsmall cell lung cancer, colorectal cancer and gastric cancer (Bradley & Koleske, 2009;
Senda et al., 2007; Yu et al., 2012). It has been indicated that RIN1 can interact with EGFR
and IR via the SH2 domain which plays an important role in cell signaling. Additionally,
RIN1 directly competes with RAF-1 for RAS binding and then blocks the RAF-1
interacting with RAS. Thus, the RIN-RAS interaction prevents the activation of the
MAPK/ERK pathway. To gain a better understanding of RIN1 function, it is important not
only to determine what is the contribution of each domain of RIN1 to selective cellular
activity, but also to discover novel binding partners. Thus, investigating potential novel
RIN1 partners may contribute to the specific cellular and molecular mechanism of RIN1
function in normal and cancer cells. To that end, we recently discovered that RIN1 interacts
with cortactin in breast cancer cells, suggesting a novel target of RIN1 as well as a possible
new mechanism of action for RIN1. Cortactin is an F-actin-associated protein that regulates
cell migration and invasion and is always involved in aggressive cancers. Therefore,
investigating the novel interaction between these two proteins is of great importance in
cancer cells behavior. Furthermore, studying RIN1:PR domain function in RTK trafficking
is critical to understanding the dynamics of EGFR trafficking. Therefore, the hypothesis of
the study is that the formation of RIN1-Rab5, RIN1-Ras and RIN1-Coractin complexes
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represent a novel mechanism of action on downstream signal transduction pathways upon
growth factor stimulation. The project focuses on three specific aims:

1-Determine the specificity requirements of this novel interaction between cortactin
and RIN1. The first aim of the study will reveal a novel RIN1 interaction partner and
determine the potential mechanism of this RIN1-Cortactin complex playing on the cell
signaling pathway. Additionally, this aim will investigate the impacts of RIN1 on cell
migration, invasion and colony formation in metastatic and non-metastatic breast cancer
cell lines.

2-Determine the role of the novel RIN1-Cortactin complex in intracellular trafficking
and signaling upon growth factor stimulation in breast cancer cells. The second aim
of this study will elucidate the role of RIN1 and its mutants on proliferation in breast cancer
cell line as well as the downstream signaling driven by EGF in cells expressing RIN1
constructs.

3-Effect of RIN1 on cell proliferation, migration and invasion in several cancer cell
lines. The third aim of the study will examine the RIN1 effect on cell proliferation,
migration, invasion and colony formation in different types of cancer cell lines including
human glioblastoma and melanoma cell lines.
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CHAPTER 2
DETERMINE THE SPECIFICITY REQUIREMENTS OF THE NOVEL
INTERACTION BETWEEN CORTACTIN AND RIN1
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2.1 Introduction
Cortactin, a noticeable actin-binding protein, was discovery as part of the Src nonreceptor tyrosine kinase pp60src (Wu & Parsons, 1993; Wu et al., 1991). Cortactin has an
important role in maintaining the actin filaments stability by interacting with Arp2/3
complex as well as assembling actin (Tehrani et al., 2007; Welch & Mullins, 2002).
Cortactin consists of several domains and interacts with numerous proteins involved in the
actin polymerization. It has N-terminal acidic domain which can bind with Arp2/3 to
regulate the actin stability (Weaver et al., 2003), followed by tandem repeat of a 37 amino
acid named cortactin repeats region. In the C-terminus, it has SH3 domain that interacts
with other proteins containing Proline Rich domain (PR), which includes the actinregulatory neural Wiskott-Aldrich syndrome protein(N-WASP) (Martinez-Quiles et al.,
2004; Mizutani et al., 2002). Furthermore, cortactin holds proline rich domain that can be
phosphorylated at tyrosine and serine sites. Thus, it is clear that cortactin domains play an
important role in mediating numerous proteins which regulate various cellular functions.
These interacting proteins can be divided into several groups: 1-Cortactin’s partners
associated with actin assembly (N-WASP, Arp2/3, Caldesmon and Actin filaments), 2Cortactin’s partners associated with phosphorylation ( ERK1/2, Src family kinases, Nck1
and Abl), 3- Cortactin’s partners associated with membrane trafficking (p120 catenin,
Dynamin2 and K+ channel Kv1.2) and 4- Cortactin’s partners associated with signal
transduction ( Grb2, BPGAP1 and ASAP1).

Cortactin is widely known to contribute in abundant of actin-drive intracellular
processes by regulating the assembly actin as well as branching actin networks. Studies
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show that cortactin acted to drive cellular membrane dynamics including lamellipodia
protrusion or vesicle movement through actin comet tails (Orth & McNiven, 2003; Weaver
et al., 2003; Weed & Parsons, 2001). Indeed, cortactin has been found at sites in cellular
protrusions, (i.e., lamellipodia and invadopodia) (Weaver et al., 2003; Yamaguchi &
Condeelis, 2007). In addition, cortactin is also phosphorylated by tyrosine and
serine/threonine kinases (Martinez-Quiles et al., 2004). Thus, cortactin can be specifically
regulated play a crucial role in membrane trafficking and signaling. Particularly, the
secretion of proteases which are essential in tumor cell metastasis like ECM- degrading
proteinases are facilitated by cortactin. Therefore, cortactin shows highly association with
cell migration and invasion (Chuma et al., 2004; Li et al., 2016; Ni et al., 2015).
Accumulating evidences have shown that cortactin plays an important role in aggressive
cancer cells. Some studies point out that the expression level of cortactin was elevated in
different type of cancers including breast cancer and head and neck tumors (Chien et al.,
2016). For instance, cortactin overexpressed in endothelial cells were discovered to have a
high motility, however, expressed mutant cortactin which can not be phosphorylated on
specific tyrosine site in cells suppressed cell migration (Huang et al., 1998). Moreover,
cortactin overexpression lead to bone metastasis increase of breast cancer cells. On contrast,
injection cells expressed a cortactin mutant which blocks tyrosine phosphorylation to intra
vessel developed less metastases (Li et al., 2001). Thus, phosphorylation of cortactin at
multiple sites is required for a fully function of cortactin. Besides, cortactin acts as a
regulator in actin dynamics responding to extracellular signaling cascades (Daly, 2004;
Lua & Low, 2005). Taken together, these characteristics of cortactin urged us to specify
the effect on cancer cell migration and invasion stimulated by IGF-1 as well as EGF in
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human breast cancer cell lines in the content of key elements associated with these
signaling receptors.

We focus on EGFR signaling and intracellular trafficking since the EGFR is comprised
in cell growth, migration as well as in cell invasion (Arteaga, 2002; Schlessinger, 2000).
In metastatic MDA-MB-231 breast cells, EGFR is overexpressed, although the
phenomenon does not relate to protein amplification (Davidson et al., 1987). Contrary to
MDA-MB-231 cells, EGFR overexpression is absent in tumorigenic but not metastatic
MCF7 breast cells (Mamot et al., 2003).

Epithelial growth factor receptor is expressed on a variety of cell types; cell survival
and proliferation are contributed to EGFR signaling. Binding of EGF to EGFR provokes
receptor dimerization, thereby promoting intrinsic tyrosine kinase activity (Yarden &
Schlessinger, 1987). Phospho-tyrosine in the cytoplasmic tail of the EGF-receptor provides
docking sites for several adaptor proteins that secure Ras activation. These events, in turn,
trigger signal transduction through various Ras effectors such as PI3K lipid kinase, RIN
protein and Raf protein kinase (Colicelli, 2004). An essential step in regulating endocytosis
of EGFR is the RIN1 activates Rab5 (Chen et al., 2001). Early endosome fusion was
supported by RIN1 which is a GEF for Rab5 (Galvis et al., 2009a; Galvis et al., 2009b).
Moreover, RIN1 binds to the phosphorylated EGFR through SH2 domain (Barbieri et al.,
2004; Barbieri et al., 2003) suggesting a mechanism for sustained RIN1 engagement via
endocytic pathways. RIN1 interacts with STAM to promote EGFR degradation to
lysosomes at later endocytosis stage (Kong et al., 2007).
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In summary, it is clear that the EGFR, RIN1 and Rab5 via Ras interactions mediate
numerous prominent cellular processes associated with cell endocytosis, migration and
proliferation. In the chapter, we describe a novel protein-protein interaction between
cortactin and RIN1 upon EGF stimulation in order to determine where this new interaction
may have a key role on several key hallmark capabilities (i.e., proliferation, invasion and
colony formation) on normal and several human breast cell lines.

2.2 Materials and Methods
Reagents
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless specified
otherwise. Dulbecco’s Modified Eagle’s Medium (DMEM) and Trypsin were obtained
from Thermo Fisher Scientic (Waltham, MA). Primary antibodies including cortactin,
Phospho-Cortactin (Tyr421), phosphor-serine, p44/42 MAPK (Erk1/2), Phospho-p44/42
MAPK (Erk1/2), Akt, phospho-Akt and GAPDH were used for western blotting and they
were all purchased from Cell Signaling Technology (Danvers, MA). RIN1 antibody were
purchased from Invitrogen (Carlsbad, CA). Anti-rabbit IgG peroxidase-conjugated
secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA), and
Lipofectamine® 2000 kit was purchased from Invitrogen (Carlsbad, CA).

Cell culture
The metastatic breast cancer cells MDA-MB-231, non-metastatic cancer cells MCF-7,
normal breast epithelial MCF-12A cell lines, human embryonic kidney (HEK) 293 cells
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and Platinum A(Plat-A) packaging cells were purchased from American Type Culture
Collection (ATCC) (Manassas, VA). The MDA-MB-231, MCF7 and HEK- 293T cells were
cultured in Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% fetal bovine
serum, 2 mM glutamine, penicillin and streptomycin. The Plat A cells were grown in
DMEM with 10% fetal bovine serum, 100 unit/ml penicillin and 100 ug/ml streptomycin,
1ug/ml puromycin and 10ug/ml blasticidin. The MCF-12A were cultured in 1:1 mixture of
Ham's F12 medium and DMEM supplemented with 5% horse serum, 20 ng/ml human
epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml bovine insulin and 500 ng/ml
hydrocortisone (Xie et al., 2001). All the cells were incubated at 37°C with 5% CO2 in
humid surroundings.

Construction of Recombinant pMX-puro retroviruses and cell lines
The cDNAs of RIN1, RIN2 and RIN3 and their mutants were sub-cloned into the pMXpuro vector as previously described (Barbieri et al., 2004). When the Plat-A cells reaches
80% confluent, DNA was transfected with lipofectamine 2000 kit and harvested for 48
hours (Kitamura et al., 2003). The supernatant containing retrovirus were collected and
filtered through 0.45 uM filter, and then added with polybrene to the target cells including
MDA-MB-231, MCF-7 and MCF-12A cells for 48 hours. Then 2 to 4ug/ml puromycin was
used to select cells for 3 days.

Lysate preparation, SDS-PAGE and Western blotting
In order to obtain the cell lysate, cells were washed once with PBS and lysed in RIPA
buffer (50 mM Tris-HCL, 150 mM NaCl, 1% NP-40, 0.1% SDS, 1% sodium deoxycholate,
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1 mM EDTA, 1 mM PMSF, 1 mM NaF, 1 mM sodium orthovanadate) for 20 minutes on
ice. Cell lysates were then centrifuged at 14,000 rpm for 10 min to obtain the supernatant
at 4°C. Laemmlli sample buffer were added to the sample with 1:1 ratio and boiled in 95°C
for 10 min. Protein was separated by SDS-PAGE gel and then transferred to PVDF
membranes. After blocking with 5% BSA for 1 hour in room temperature, target proteins
were detected with the specific antibodies.

GST-fused protein purification
The pGEX-4T1 constructs (SH3-Cortactin) were transfected in BL21 (DE3) RIPL
Escherichia coli (E. coli). Bacteria containing these plasmids were induced with 0.25 mM
IPTG for 3 hr. Bacteria were collected and resuspended in extraction buffer (50 mM TrisHCl, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1mg/ml lysozyme, 10μg /ml
DNAse, 2 μg /ml leupeptin, 2μg/ml aprotinin), lysed by sonication and then incubated with
1% Triton X-100. Supernatant were collected and centrifuged at 46,000 rpm for 30 min.
Samples were collected and fractionated by GSH-affinity column. Eluates were analyzed
by SDS-PAGE gel and followed by western blot (Einarson et al., 2007).

Pull-down assay
For in vitro studies, fusion proteins were expressed and purified as previously described
in the protein purification section. For the GST-Pull-down assay, 100 ul of glutathione
Sepharose beads were blocked with PBS containing 0.5% BSA for 1 h at 4°C. GST-fused
protein was added and rocked for 1 h at 4°C in lysis buffer (PBS containing 0.3% TritonX100, 1 mM PMSF, 10 mM NaF, 0.5 mM Sodium orthovanadate). After incubation, beads
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were washed three times using lysis buffer and centrifuged at 1000 rpm for three minutes
each. Bound proteins were diluted by the addition of 4X loading buffer. Target proteins
were analyzed using SDS-PAGE, following western blotting with specific antibodies (Bain
et al., 2017).

Immunoprecipitation assay
Cells were lysed on ice using lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton). Cell lysate were incubated with appropriate antibodies overnight
at 4°C. Then, antigen-antibody complex was immobilization with protein G agarose beads
(Thermo Fisher Scientic, Waltham, MA) at 4°C for 3 hours. After incubation, beads were
centrifuged using 2000 rpm for 2 minutes and washed with lysis buffer three times. After
that, samples were resuspended in loading buffer and boiled for 10 minutes. Then, target
proteins were analyzed using by SDS-PAGE, and western blotting with specific antibodies
(DeCaprio & Kohl, 2017).

Immunofluorescence assay
For immunostaining, cells were seeded on glass coverslips in 24-well plates. After
MDA-MB-231 cells reached 90% confluence, pEGFP-RIN1 and pERPF-cortactin were
transfected with lipofectamin 2000 and incubated between 12-24 hours. Cells were washed
with PBS, and then stained with 4% paraformaldehyde in PBS at room temperature for 20
min. Cells were washed three times with PBS and coverslips were mounted with a
fluorescent mounting medium (Thermo Fisher Scientic, Waltham, MA)(Koh, 2013). Then
the fixed cells were examined with an Olympus Fluoview laser scanning confocal BX61
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by using the appropriate filter for GFP and RFP fluorochromes. Images were merged and
aligned using Adobe Photoshop 6.0 (Adobe Systems, Mountain View, CA).

Cell Proliferation Assay
Cells (5 × 104) expressing RIN1, GFP or the other mutants were seeded in 96-well
plates, and incubated for 24 hours. Then the cells were incubated in serum free media for
24 hours and then used 10% serum or EGF to stimulate for additional 24 hours. MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (10 ul of 5 mg/ml)
was added to the media and cells were incubated at 37°C for 4 hours. After incubation, 150
ul DMSO was added to each well and the produced formazan was equantiated by
spectroscopy at OD490 nm (Lai et al., 2018).

Wound healing assay
Transfected cells (2 × 105) were seeded on 12-well plates and grown in completely
media to reach 80% confluence. After that, the cells were starved for 24 hours and 200 ul
pipette tips were used to scrape the monolayer to make the cell-free area. Cells were washed
once with PBS and the distance of the gap was determiend. Then cells were incubated for
24 hours in the presence of EGF (50 ng/ml) or 10% FBS. Wound closure was measured
after 24 hours using Bright-field microscope as described (Mezi et al., 2012).

Transwell invasion assays
The transwell inserts were coated with 100 ul Matrigel (1:20 dilution) (Corning, NY).
Cells (2.5× 105) were seeded to the upper well in serum free meida. Lower chamber was
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added with DMEM supplemented with 10% FBS. After that, the plate was incubated at
37°C for 16-24 hours. After the incuabtion, cells were washed with PBS to remove the
non-migrated cells in the upper chamber. Then, membranes were fixed with 100 %
methanol and then stained with 0.1% crystal violet for additional 20 minutes. After washing
3 times with PBS, dry the insert membrane completely. Count the stained cells number
under a bright-field microscope (Justus et al., 2014; Marshall, 2011).

Soft agar colony formation assay
Transfected cells (1 × 104) were seeded into 24-well plates containing 0.35% lowmelting temperature agarose. The cells were plated over a 0.75% agarose layer with
DMEM and serum. Cells were allowed to grow and form colonies for 15-20 days. Colonies
were washed with PBS and then stained with crystal violet for 30 minutes. Then the
colonies were washed with autoclaved dd-H2O for several four times. The colonies were
photographed under low magnification(4x) (Borowicz et al., 2014).

Statistical analysis
All experiments were carried out in triplicate and repeated at least three times. All error
bars represent the mean ± SEM and statistical significance was performed by two-tailed
student’s t test. *P<0.05 or lower was considered statistically significant.
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2.3 Results
2.3.1 RIN1 inhibits cell migration in normal and metastatic breast cell line
To investigate the role of RIN1 on normal and metastatic breast cell lines, all cells were
transfected with PMX-GFP and PMX-RIN1 using a retrovirus system as previously
described (Barbieri et al., 2004). Stable cell lines overexpressed GFP and RIN1 were
stimulated with 10% FBS. The cell migration assay was used the 200 ul pipette tips to make
the cell free area and then measured after 24 hours with 10% FBS stimulation. As shown
in Figure 2.1, RIN1 inhibits cell migration in MCF-12A cells as well as MCF-7 and MDAMB-231 cells.
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Figure 2.1. RIN1 inhibits cell migration in normal and metastatic breast cell line.
Normal and metastatic breast cancer cells overexpressed GFP and RIN1 were incubated
until reaching 80% confluence. A cell free area was created, and cells were allowed to
migrate in 10% FBS. The mean gap distance was measured and calculated as mentioned in
the material and methods parts. The quantification data were analyzed associated with cell
migration results. A) In MDA-MB-231cells, the cells were allowed to migration for 24
hours. B) MCF-7 cells migrated for 48 hours and then analyzed. C) MCF-12A were
cultured and migrated for 16 hours. Error bars represent the mean ± S.E.M from more than
three individual experiments. **P<0.01 and ***P<0.001 were reported using two-tailed
t-test.
2.3.2 RIN1 prevents cell invasion in breast cancer cells
Since the ability of cell invasion is a hallmark of cancer cells and relating with the poor
prognosis in some types of cancers (Clark & Vignjevic, 2015), it is important to detect the
role RIN1 plays in breast cancer cells. The cells overexpressing GFP and RIN1 were seeded
in the Falcon transwell insert and incubated for around 24 hours with 10% FBS inducement.
The results showed that there was a significantly decreased the number of the invaded cells
in the breast cancer cells overexpressed RIN1 comparing with GFP cells, which suggested
that RIN1 had the key role in inhibiting the cell invasion (Figure 2.2).
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Figure 2.2. RIN1 prevents cell invasion in breast cancer cells. Cell expression either
GFP and RIN1 were seeded in the transwell insert and incubate for 24 hours with 10%FBS
in the bottom well. After that, the cells were fixed and stained with 0.01% crystal violet.
The data was analyzed with image J. The quantification data were analyzed associated with
cell invasion results. A) MDA-MB-231 cells, B) MCF-7 cells. Error bars represent the
mean ± S.E.M from more than three individual experiments. **P<0.01 and ***P<0.001
were reported using two-tailed t-test.
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2.3.3 Tumor formation is inhibited with RIN1 overexpression in breast cancer cells
Independent of anchorage growth is the ability of transformed cells to grow
independently of solid surfaces and can be considered as metastatic potential (Mori et al.,
2009). The soft agar colony formation assay is a mature technique and is widely used for
the test of malignant transformation of cells (Borowicz et al., 2014). On the basis of the
results showed in the migration and invasion, RIN1 had the ability to inhibit the cell
migration and invasion. It was necessary to indicate the RIN1 influences on the ability of
colony formation in metastatic and non-metastatic breast cancer cell lines. As expected,
RIN1 overexpression reduced not only the size but the number of colonies compared with
control in both breast cancer cell lines (Figure 2.3).
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Figure 2.3. Tumor formation is inhibited with RIN1 overexpression in breast cancer
cells. Breast cancer cell lines were plated in the layer of 0.35% agarose, cells were allowed
to grow at 37℃. 100ul of 10% FBS growth media was added to the well every 2-3 days.
After 15 days, the colonies were stained with 0.01% crystal violet and photographed under
low magnification. The quantification data were analyzed associated with cell colony
formation results. A) MDA-MB-231 cells, B) MCF-7 cells. Error bars represent the mean
± S.E.M from more than three individual experiments. **P<0.01 and ***P<0.001 were
reported using two-tailed t-test.
2.3.4 Effective of RIN1 domains on cell migration and invasion in MDA-MB-231 cells
As RIN1 has already shown the inhibitory effect on breast cancer cell migration,
invasion and colony formation, the further demonstration of specific domain function in
RIN1 is important. The N-terminus (RIN1: R2), C-terminus (RIN1: R3) including VPS9
(RIN1: R4) and RA (RIN1: R5) were subcloned into the PMX-Puro vector and stable
overexpressed in MDA-MB-231 cells as described in material and methods. The migration
assay was studied and it was discovered that RIN1: R2 stimulated cell migration whereas
R3 inhibited cell migration (Figure 2.4a). Comparing with individual domains in Cterminus, the results showed that both VPS9 and RA domain had the ability to suppress
cell migration comparing with 231-GFP cells as well as 231-RIN1 cells. Cell expressing
GFP, RIN1 and its specific individual domains were seeded into the transwell-inserted and
incubated for 24 hours in the presence of 10% FBS and the cell invasion ability was
measures by the transwell assay. Figure 2.4b described that RIN1-R3 diminished the cell
invasion. On contrast, RIN1-R2 showed the increasement of invasive potential comparing
with the control cancer cells. Additionally, the VPS9 and RA alone also showed inhibitory
function in cell migration compared as RIN1: WT (Figure 2.4c).
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Figure 2.4. Effective of RIN1 domains on cell migration and invasion in MDA-MB231 cells. A) RIN1:R2 (SH2 and proline rich domains), RIN1:R3 (VPS9 and RA domains),
R4 (VPS9 domain) and R5(RA domain) were transfected into MDA-MB-231 cells and
each cell lines were seeded into the transwell insert and invaded for 24 hours. The cells
were fixed and stained with 0.01% crystal violet and photographed under 10x
magnification. A quantification of invaded cells was calculated associated with the invasion
assay results. B) Cell expressing GFP or RIN1and its different domains were plated in 12well plate and made the scratch line with 200ul pipette tips. The cells were allowed to
migration for 24 hours. The gap areas were photographed and analyzed. The data were
analyzed with image J. C) RIN1 and each individual domain were transfected into cells
and migrated for 24 and 48 hours. Quantification data was analyzed related with migration
results. Error bars represent the mean ± S.E.M from more than three individual experiments.
* P<0.05, **P<0.01 and ***P<0.001 were reported using two-tailed t-test.
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2.3.5 Effective individual domains of RIN1 on tumor formation in cancer cells
As data showed above, cells overexpressing RIN1 decreased both the number and size
of the colonies formed by cancer cells. To deeply understand the role RIN1 plays in colony
formation, it was vital to know the influence of individual domains of RIN1 in the process.
Cells overexpressing VPS9 and RA domains formed less amount of colonies compared
with control cells (Figure 2.5).
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Figure 2.5. Effective individual domains of RIN1 on tumor formation in breast cancer
cells. MDA-MB-231 expressed GFP, RIN1, RIN1:R4 and RIN1:R5 were plating in low
concentration of agarose layer and cultures for 15 days with 10% FBS stimulation.
Colonies were stained with 0.01% crystal violet and the pictures of colonies were taken
and calculated each well. The quantification data were analyzed corresponding to cell
colony formation results. Error bars represent the mean ± S.E.M from more than three
individual experiments. **P<0.01 and ***P<0.001 were reported using two-tailed t-test.
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2.3.6 Differential effect of RIN1 domain mutants on migration and invasion in MDAMB-231 cells
To specify which domains of RIN1 is required for the inhibitory effect on the cancer
migration and invasion, some specific point mutants in SH2, VPS9 and RA domains were
created and expressed in MDA-MB-231 cells as listed in material and methods:
RIN1:R94A, RIN1:ΔPR, RIN1:Y561F and RIN1:R664A (Galvis et al., 2009b). The
RIN1:Y561F and RIN1:R664A overrode the inhibitory effect displayed by its domain. On
the opposite, the RIN1:R94A and RIN1: ΔPR showed the ability to reduce the cell
invasion (Figure 2.6).
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Figure 2.6. Differential effect of RIN1 domain mutants on migration and invasion in
MDA-MB-231 cells. A) MDA-MB-231 cells overexpressing GFP, Rin1:WT and the
following mutants: ΔPR and R94A, were seeded into transwell insert as depicted in
Material and Methods. The invaded cells were counted after 24 hours. The quantification
data were analyzed associated with cell invasion results. B) MDA-MB-231 cells
overexpressing GFP, Rin1: WT and the following mutants: Y561F and R664A were plated
into 12-well plate, cell free areas were created and induced by 10% FBS for 24hours. The
scratch edge was measured and calculated. The quantification data were analyzed related
with cell migration results. Error bars represent the mean ± S.E.M from more than three
individual experiments. *P<0.05, **P<0.01 and ***P<0.001 were reported using twotailed t-test.
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2.3.7 RIN1 key point mutants promoted tumor formation in MDA-MB-231 cells
In the development of tumors, there are two stages in the main phase of tumor formation:
primary colony formation and hyperproliferative growth in the initial phase of premetastatic, and secondary colony formation during post-metastatic phase (Hanahan &
Weinberg, 2000). As described in 2.3.5, RIN1 key points mutations including RIN1:Y561F
and RIN1:R664A inhibited cell migration. To further detect the role that RIN1 mutations
play in the metastatic step, RIN1-Y561F and RIN1:R664A were plated in the soft agar and
observed after 15 days. Interestingly, both mutants created more, and larger colonies than
231-GFP and 231-RIN1 cells (Figure 2.7).
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Figure 2.7. RIN1 key point mutants promoted tumor formation in MDA-MB-231 cells.
MDA-MB-231 expressed GFP, RIN1, Y561F and R664A were plating in low concentration
of agarose layer and cultures for 15 days with 10% FBS stimulation. Colonies were stained
with 0.01% crystal violet and the pictures of colonies were taken and calculated each well.
The quantification data were analyzed associated with cell cony formation results. Error
bars represent the mean ± S.E.M from more than three individual experiments. **P<0.01
and ***P<0.001 were reported using two-tailed t-test.
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2.3.8 RIN1 interacts with Cortactin in MDA-MB-231 cells
To investigate the new interacting partner, two techniques were taken out, which are
immunoprecipitation and GST-pull down. Endogenous RIN1 in MDA-MB-231 cells was
indicated to interact with endogenous level of Cortactin. Furthermore, MDA-MB-231 cells
overexpressing pEGFP-RIN1 and pEGFP-Cortactin showed strong association with each
other using immunoprecipitation (Figure 2.8a). A GST-pull down assay was taken out by
collecting cell lysate from MDA-MB-231 cells stable overexpressing RIN1, and the GSTlabeled protein (GST-SH3-cortactin) was purified by GSH column. Additionally, GST
alone was used as negative control. It had a strong band showing that RIN1 interacts with
cortactin-SH3 domain (Figure 2.8b).
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Figure 2.8. RIN1 interacts with Cortactin in MDA-MB-231 cells. A) MDA-MB-231
cells were lysed with IP lysis buffer, and the cell lysate were incubated with RIN1 antibody
overnight, the complex was incubated with protein A/G for 3 hours at 4℃. After that, the
complex was washed three times with TBST buffer and then western blot by using cortactin
antibody. Endogenous level: MDA-MB-231-RIN1 cells were transfected with pEGFP cortactin for 48 hours, lysed with IP lysis buffer, afterwards incubated the cell lysate with
RIN1 antibody overnight, then the complex was incubated with protein A/G agarose for 3
hours at 4℃. After that, the complex was washed three times with TBST buffer and then
western blot by using cortactin antibody. B) GST pull down assays: MDA-MB-231-RIN1
cell lysate incubated with GST-SH3-cortactin protein for 3 hours and then immunoblotting
with RIN1 antibody. The results showed that RIN1 interacts cortactin via SH3 domain.
Error bars represent the mean ± S.E.M from more than three individual experiments.
**P<0.01 and ***P<0.001 were reported using two-tailed t-test.
2.3.9 Cortactin co-localized with RIN1 along plasma membrane in MDA-MB-231 and
HEK-293 cells
Previously results have shown that RIN1 inhibited breast cancer migration and invasion
and interacted with cortactin in vitro. Thus, it would be interesting to find the location of
RIN1 and cortactin in cells. Cortactin and RIN1 were transfected in MDA-MB-231 cells
and then serum-stimulated for 24 hours. Several filopodia were formed after stimulation of
serum. Moreover, cortactin and RIN1 were colocalized at the plasma membrane (Figure
2.9a and 2.9b).
Cortical actin cytoskeleton is regulated by growth factor and cortical actin cytoskeleton
is the basis of a variety of cellular processes. Formation of the dynamic actin network
through the Arp2/3 is highly regulated by cortactin which is essential to the cell migration
and invasion (Lynch et al., 2003). The HEK-293 cells were transiently transfected with
GFP-RIN1 and RFP-Cortactin, serum starved for 24 hours and then used 100ng/ml EGF
to culture the cells. After stimulation, the cells were fixed by 4% paraformaldehyde for 20
minutes in room temperature. Following EGF stimulation in HEK-293 cells, cortactin and
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RIN1 were co-localized in plasma membrane in HEK-293 cells (Figure 2.9c).
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Figure 2.9. Cortactin co-localized with RIN1 along plasma membrane in MDA-MB231 and HEK 293 cells. A) MDA-MB-231 cells were co-transfected with pEGFP-RIN1
and pERFP-Cortactin, incubated in 10% FBS for 24 hours and then fixed. B) pEGFP-RIN1
and pERFP-Cortactin were co-transfected into the HEK 293 cells, and then the cells were
starved and induced by 100ng/ml EGF for 24 hours.
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2.3.10 Cortactin mutant affects the interaction with RIN1
To detect the importance of SH3 domain in cortactin, a cortactin: W525K mutant was
created and transient transfected in MDA-MB-231cells (IBC approval: 300198). The
results showed that cell overexpression Cortactin: W525K decreased the interaction with
RIN1 significantly (Figure 2.10a). Moreover, in HEK-293 cells overexpression
cortactin:3D (Y421D,Y466D,Y482D), which mimics phosphotyrosine, did not affect the
interaction with RIN1, whereas cortactin: 3F (Y421F,Y466F,Y482F), weakened tyrosine
phosphorylation of cortactin (Rosales et al., 2012), and blocked the interaction between
cortactin and RIN1 (Figure 2.10b). Some studies showed that protein containing SH3
domain interacts with proline rich domain in RIN1(Kong et al., 2007). The deletion of
proline rich domain in RIN1 was carried out to demonstrate the importance of proline rich
domain in protein and protein interaction. The data indicated that the proline rich domain
was essential for the interaction with cortactin (Figure 2.10c).
A)
WT W525K

RIN1 bound(relative units)

IP: RIN1

1.2

Cortactin

WB: cortactin
IgG
Cortactin

Input
RIN1

1
0.8

**

0.6
0.4
0.2
0
WT

W252K

cortactin

65

B)
3D WT
RIN1 bound(relative units)

3F
IP: RIN1

Cortactin

WB: cortactin

IgG

1.2
1
0.8

***

0.6
0.4

***

0.2
0
WT

3D

3F

Cortactin

C)

IP: RIN1

WT
rin1 bound(relative units)

ΔPR

Cortactin

WB: cortactin
IgG

Input

Cortactin

1.4
1.2
1
0.8
0.6
0.4

**

0.2
0
ΔPR

WT

RIN1

RIN1

2.10. Cortactin mutant affects the interaction with RIN1. Immunoprecipitation (IP)
results demonstrating an in vivo interaction between RIN1 and cortactin. A) HEK cells
were co-transfected with pEGFP- RIN1 and either pERFP -cortactin or pcDNA-FLagcortactinW525K. The protein complexes were immunoprecipitated using anti-RIN1
antibody and then visualized by western blotting (WB) with anti-cortactin antibody.
B) The left lane is the MDA-MB-231-RIN1 cells overexpressed cortactin3F(Y421,466,482F), lacks phosphorylated tyrosines, decreased the interaction between
cortactin and RIN1, the middle lane overexpressed cortactin 3D(Y421,466,482D) which is
a phosphotyrosine mimic, compared with cortactin-wt, did not have too much effect on the
interaction. C) MDA-MB-231 cells were transfected with pEGFP- RIN1 and pEGFPRIN1ΔPR for 48 hours, lysed with IP lysis buffer. Cell lysate were incubated with RIN1
antibody overnight and then rocked with protein A/G agarose for 3 hours at 4℃. Then the
interaction was determined by western blotting using cortactin antibody. The results
showed that in vivo, RIN1ΔPR, a cortactin binding deficient mutant that lacks its PR
domain, was unable to participate cortactin. Error bars represent the mean ± S.E.M from
more than three individual experiments. **P<0.01 and ***P<0.001 were reported using
two-tailed t-test.
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2.3.11 RIN1 blocks cortactin induced migration
Cortactin and RIN1 interacts with each other in cancer cells has been demonstrated in
prior studies. Thus, determination of the RIN1 effect on the cortactin induced migration
was necessary. First, RFP-Cortactin was transfected individually to the HEK-293 cells,
comparing to the control, the results showed that overexpressed cortactin stimulated cell
migration. Contrary to the stimulation by cortactin, RIN1 inhibited cell migration.
Surprisingly, transfected with RIN1 and cortactin together to the HEK-293 cells, it
promoted cell migration comparing with RIN1 overexpressed cells. However, it blocked
cell migration in comparison with cells overexpression cortactin (Figure 2.11). The pictures
exhibit the efficiency of the transfection. Green presents RIN1 overexpression and red for
the cortactin.
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Figure 2.11. RIN1 blocks cortactin induced migration. A) HEK cells were transfected
with pEGFP-C1 and pERFP-Cortactin for 48 hours. And then the cell free areas were
formed using 200ul tips. The areas were taken pictures and analyzed at 0hour and 36 hours.
The results showed that over-expressed GFP would induce cell migration comparing with
control cell. B) pEGFP-C1, pEGFP-RIN1, pERFP-Cortactin, pEGFP-RIN1+ pERFPCortactin were transfected into HEK cells and cultures for 24 hours. Migration assay were
carried out to detect the cell migration rate. The pictures were taken by fluorescence
microscope to prove the transfection efficiency. Error bars represent the mean ± S.E.M
from more than three individual experiments. **P<0.01were reported using two-tailed ttest.
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2.3.12 RIN1 decreased cortactin tyrosine and serine phosphorylation upon EGF
stimulation
Previous study shown that cortactin was involved in cancer cell migration through
EGF-Src-Cortactin pathway (Mezi et al., 2012). On the other hand, cortactin is
phosphorylated by serine/threonine kinase such as Erk/MAP kinase. Cortactin is reported
to promote cell migration by regulating the Erk pathway (Ni et al., 2015). To investigate
the mechanism of RIN1 inhibiting the cortactin regulated migration, the level of
phosphorylated cortactin was detected. Surprisingly, overexpressing RIN1 inhibited the
expression of phosphorylated cortactin at tyrosine 421 and total serine site in MDA-MB231(Figure2.12a) as well as MCF7 cells (Figure 2.12B) upon EGF stimulation.
Interestingly, cells overexpressed RIN1 mutants like Y561F, R629A showed strong ability
to augment the expression of phosphorylation level of cortactin at tyrosine site (Figure
2.12a). Additionally, phosphorylated tyrosine cortactin was blocked in MCF-12A and
MDA-MB-231cells with 10% FBS stimulation (Figure 2.12c). These results strongly
presented RIN1 inhibited cortactin phosphorylation and blocked the Src-cortactin and Erkcortactin pathway.
Afterwards, the HEK cells were co-transfected with pEGFP-RIN1 and pEGFP cortactin,
cortactin antibody was used to incubate with cell lysate, and then immunoblotted with
phosphor-Tyr421 and phospho-(Ser/Thr) antibody. The results showed that cortactin
associated with both phosphorylated cortactin at both tyrosine and serine sites (Figure
2.12d). Moreover, the interaction with RIN1 and phosphorylation of cortactin were also
detected (Figure 2.12e). The results revealed that RIN1 associated with serine
phosphorylation of cortactin in a lower density than tyrosine phosphorylation of cortactin.
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Figure 2.12 RIN1 decreased cortactin tyrosine and serine phosphorylation upon EGF
stimulation. A) MDA-MB-231 cells overexpressing GFP, RIN1 and its mutants were
cultured in serum free media for 24 hours, following by stimulateing with 100ng/ml EGF.
Total protein lysates were prepared using RIPA buffer as meterail described. Total proteni
plysate were subjected into western blot and using phosphp-Ser/Thr, phosphocortactin(Tyr421),cortactin and GAPDH antibodies to detect. B) GFP and RIN1 were
stable transfected in MCF-7 cells, serum starved for 24 hours and driven by 100ng/ml EGF.
Then the cells were lysed and analyzed by western blot. C) Overexpression of GFP and
RIN1 inMDA-MB-231 and MCF-12A cells were cultured for 24 hours with 10% FBS
inducement. After that, cells were lysed and using western blot to anayze the expression of
specific protein. D) HEK cells were co-transfected with pEGFP-RIN1 and pEGFPCortactin and incubated for 48 hours. The cells were immunoprecipitated with antiCortactin antibody and the association with phosphor-serine and phosphor-cortactin
(Tyr421) were visualized using anti-phosphoserine and anti-phospho-cortactin antibodies.
E) HEK cells were co-transfected with pEGFP-RIN1 and pEGFP-Cortactin and incubated
for 48 hours. The cells were immunoprecipitated with anti-RIN1 antibody and the
association with phosphor-serine and phosphor-cortactin (Tyr421) were visualized using
anti-phosphoserine and anti-phospho-cortactin antibodies. Quantification data were
analyzed relating to western blot results using Image J software. Error bars represent the
mean ± S.E.M from more than three individual experiments. **P<0.01 and ***P<0.001
were reported using two-tailed t-test.
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2.4 Discussion
Some studies show that metastasis is the key factor that cause cancer patients death
(Mehlen & Puisieux, 2006). Metastasis is an extremely complicated process including
tumor cells detach from primary tumor and migrate into the other distant organs (BravoCordero et al., 2012). Numerous researches point out that EGF plays a vital role in the
process of the cancer migration, invasion and anchorage-independent growth which related
with cancer metastasis (Gao et al., 2011; Lu et al., 2001; Price et al., 1999; Ye et al., 2018).
It has been indicated that downstream signaling pathways such as RAS-RAF-MAPK and
PI3K-AKT pathway are activated by receptor tyrosine kinases like EGFR (Freudlsperger
et al., 2011; Scaltriti & Baselga, 2006). Additionally, Src has been defined as an EGFR
signaling component and has an effect in cell migration, proliferation and invasion (Kopetz,
2007). Src activation always observed on the cancers (Irby & Yeatman, 2000). Moreover,
the relationship between Src and EGFR has well established (Irwin et al., 2011).
Cortactin, a well-known actin binding protein, binds to Arp2/3 complex to stable the
actin filaments (Uruno et al., 2001). Moreover, cortactin has been verified to participate
the assemble the cell edge protrusions including lamellipodia and filopodia (Tehrani et al.,
2007). Cortactin phosphorylated by tyrosine and serine/threonine kinases which involved
in Src and Erk pathways have a crucial effect on the membrane trafficking (MartinezQuiles et al., 2004). Additionally, cortactin is vital for formation of invadopodia relating to
the cancer cell metastasis (Yin et al., 2017). Cortactin has been noticed a high association
with malignance of cancers. Some cancers like breast cancer as well as head and neck
tumors, cortactin has been presented overexpressed (Chien et al., 2016). Variety studies
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have indicated that overexpression of cortactin promotes cell migration, invasion leading
to tumor metastasis (Chuma et al., 2004; Liu et al., 2017).
Cortactin consists of multiple domains: N-terminal acidic and actin binding domains in
the N terminal, proline rich and SH3 domains in the C terminal (Uruno et al., 2001).
Cortactin interacts with several proteins which regulate the diverse signaling pathways.
Numerous cytoskeleton proteins act like cortactin interaction partners indicating that
cortactin has crucial effect on regulating cell cytoskeleton and arrangement of the
membrane trafficking (Weaver, 2008).
Previous studies show that cortactin can be phosphorylated by Src which promotes
breast cancer migration (Mezi et al., 2012). Moreover, the other study also points out
cortactin enhances cell proliferation as well as colony formation in colon cancers by
regulating ERK pathway (Ni et al., 2015). All those studies have shown that cortactin has
a close relationship with cancer migration and invasion upon EGF stimulation.
In the present study, it shows cortactin has the function to enhance cell migration and
with EGF stimulation, it locates on the cell membrane ruffles which consistence with
previous study. RIN1, a multifunctional protein, binds with Ras and affects Ras-Raf-Erk
pathway signaling by competing with Raf (Shi et al., 2005), additionally, it can regulate
cell cytoskeleton by interacting with ABL1/2; also, it acts like GEF and activates Rab5 by
exchanging inactivate phase to activate phase (Wang et al., 2002). This work shows that
RIN1 may act as a novel cortactin interaction partner. Co-immunoprecipitation and GST pull down assay showed that RIN1 interacted with Cortactin SH3 domain through its
proline rich domain in breast cancer cells. Additionally, cortactin: W525K mutant (Rosales
et al., 2012), a mutant in SH3 domain in cortactin, reduced the binding ability of proline
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rich domain in RIN1 suggesting that SH3 domain is important in the interaction.
Furthermore, deletion of proline rich domain in RIN1 decreased the binding intensity with
cortactin, indicating proline rich domain is essential in the interaction.
To elucidate the role of RIN1 in the cancer cells, RIN1 and its mutants has been
transfected into the breast cancer cells. And the results discovered that overexpression
RIN1 inhibited cell migration, invasion and colony formation. For the deep understanding
of RIN1 function, RIN1 mutants has been created and expressed. The results showed that
VPS9 and RA domain inhibited cancer cell characters, whereas SH2 and Proline rich
enhanced. It may can be explained that:
1. SH2 domain interacts with EGFR and regulate downstream cell signaling.
2. RIN1 competes with Raf and blocks RAS-RAF-MAPK pathway.
3. Activation of Rab5 may lead to inhibition of cancer invasion, migration and colony
formation.
The different specific point mutant in individual domain proves this speculation. First,
the mutant of R94A, which influences the interaction with EGFR via SH2 domain showed
stronger inhibitory effect on the cancer cell invasion (Barbieri et al., 2003). This
demonstrates the importance of SH2 domain in binding with EGFR and promotes cell
invasion. Second, RIN1:Y561F in VPS9 domain, partially decreased interaction with Rab5
and the results showed it promoted cancer cell migration and colony formation. The similar
results happened in RIN1:T580A, which completely lost interaction ability with Rab5
(Galvis et al., 2009a; Galvis et al., 2009b). No activation of Rab5 leads to enhance cancer
migration and colony formation, illustrating the importance of activation Rab5. Third, the
mutant in RA domain including both RIN1 mutants (R629A and R664A) (Mustafi &
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Barbieri, 2016), which diminish the binding ability with RA domain, promoted cell
migration and colony formation in breast cancer cells. These findings are strong evidence
of RIN1 inhibits cancer cell invasion and migration by blocking Ras-RAF-MAPK pathway.
Cortactin promotes cancer migration and invasion and RIN1 plays an opposite role. What
is the mechanism of RIN1-Cortactin complex in the cell signaling pathway? In order to
explain this question, phosphorylation of cortactin has been detected. Interestingly, the
results presented that overexpression RIN1 inhibited tyrosine phosphorylated cortactin and
serine phosphorylation of cortactin upon EGF stimulation. It is surprisingly to find RIN1
may suppress cortactin phosphorylation by inhibiting Src and Erk pathway.
Overall, the current study indicated that overexpression RIN1inhibited cell migration,
invasion and colony formation which all involved in metastasis in invasive and noninvasive breast cancer cells. It provides a novel RIN1 interaction partner, cortactin, and
elucidates the potential mechanism of RIN1-Cortactin complex in cellular signaling
pathway with EGF driven. It remains further elucidating of RIN1 function in proliferation
and the effect of cell signaling such as Ras-RAF-MAPK and PI3K-AKT pathway.
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CHAPTER 3
DETERMINE THE ROLE OF NOVEL RIN1-CORTACTIN COMPLEX IN
INTRACELLULAR TRAFFICKING AND SIGNALING UPON GROWTH
FACTOR STIMULATION IN BREAST CANCER CELLS
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3.1 Introduction
Hyperactivation of EGFR is associated with proliferative disorders, consisting of
progression of specific tumors (Wieduwilt & Moasser, 2008). For healthy cells, it is very
dangerous if it does not properly regulate EGFR activation, signaling, attenuation and
degradation. Abnormal expression and dysregulation of EGFR in cell trafficking plays an
important role in tumorigenesis since several EGFR mutations have been reported in
numerous types of cancers (Lafky et al., 2008; Lee et al., 2006; Paez et al., 2004).
Trafficking as well as singling defects of the EGFR are associated with mislocalization,
poor downregulation, signaling enhancement, which in turn can induce and promote
progress of cancer (Roepstorff et al., 2008; Sorkin & von Zastrow, 2009; Yarden & Pines,
2012).
In general, the network of the EGFR system is tightly coordinated by precise
biochemical modifications of the receptor tail. Once ligand binding, the activated and
dimerized EGFR autophosphorylates on multiple tyrosine sites on the cytoplasmic tail.
After that, the multiple downstream effectors are recruited mediating by the
phosphorylated residues, which in turn modulates both signaling and membrane trafficking.
Interestingly, upon EGF stimulation several small GTPases are being activated, including
Rho, Rac1, CDC42, Ras and Rab proteins. Actin polymerization is regulated by Rho and
Rac1 small GTPases and produces lamellipodia, while another member of the rho family,
CDC42, triggers filopodia formation (Nobes & Hall, 1995). However, Ras and Rab
proteins regulate intracellular signaling and membrane trafficking drive by EGF
(Malumbres & Barbacid, 2003; Stenmark & Olkkonen, 2001).
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The small GTPase Ras is activated by the addition of EGF via the Ras GEF, son of
sevenless homolog 1 (SOS1) (Chardin et al., 1993). In this case, the growth factor receptorbound protein 2 (Grb2), which binds activated EGFR through its SH2 domain (Batzer et
al., 1994), which in turn will control downregulation through internalization and also
activation of signaling cascades through Grb2-SOS1 (Chardin et al., 1993). Interaction of
Ras in the GTP-bound form and RAF initiates the MAPK (mitogen-activated protein
kinase) signaling cascade as well as activation of PI3K/Akt pathway producing PI3,4,5P
lipids (Rodrigues et al., 2000) and PLC-1-PKC pathway (Wee & Wang, 2017). The RasRaf-Erk pathway are the most crucial signaling cascades in mediating the EGFR induced
biological activities, including cell proliferation, invasion, and migration (Lewis et al.,
1998; Morrison, 2012). Upon Erk activation, Erk will translocate to the nucleus to activate
numerous transcription factors including c-Myc (Murphy & Blenis, 2006). Additionally,
activated Erk also can activate ETS family, SP-1 and c-JUN (Quantin & Breathnach, 1988;
Stacey et al., 1987; van der Geer et al., 1995).
The EGFR-PI3K-AKT/PKB pathway is commonly hyperactive in cancer. It negatively
controls the nuclear translocation of several proteins, including the activity of ForkheadBox-O family of transcription factors (FOXO1, 3, and 4). Taken together, in the nucleus,
all these activated factors are localized, they control several target genes involved in a
multiple process: cell proliferation, survival, metabolism and apoptosis (Eijkelenboom &
Burgering, 2013).
Another EGFR-binding adaptor protein is RIN1, a key Rab5 GEF in the activation of
Rab5 (Kajiho et al., 2011; Kimura et al., 2006; Saito et al., 2002; Su et al., 2006; Tall et al.,
2001). Rab5 activation is mediated by a GEF that switches the GDP form to GFP form.
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Numerous proteins have been proved as Rab5 GEFs which contain VPS9 domain catalyze
nucleotide exchange such as RABGEF1( also known as Rabex-5) (Horiuchi et al., 1997),
ALS2 (Topp et al., 2004), Rin 1, 2, and 3 proteins (Kajiho et al., 2011; Kimura et al., 2006;
Saito et al., 2002; Tall et al., 2001), Rin-L(Woller et al., 2011) and GAPVD1 (also known
as GAPex-5 and Rap6) (Hunker et al., 2006; Lodhi et al., 2007; Su et al., 2006). Most
studies have shown that Rab5 was involved in multiple biological functions, consisting of
regulation early endocytic events (Zerial & McBride, 2001; Gorvel et al., 1991; Stenmark
et al., 1994), receptor internalization (Barbieri et al., 2000), actin remodeling (Lanzetti et
al., 2004), and signaling to the nucleus (Miaczynska et al., 2004). Therefore, Rab5
functions are likely to be accomplished by different Rab5 GEFs.
In summary, it is clear that the EGFR mediates the activation of Rab5 and Ras via two
key proteins, SOS and RIN1. These two proteins interact with EGFR upon EGF stimulation.
Thus, a combination of this temporo-spatial dynamics during the activation of these two
small GTPase originate specific signal transduction that could regulate proliferation,
invasion and colony formation, respectively. In this chapter, we describe the effect of
several RIN1 constructs on the activation of several signaling molecules including Erk,
Akt, FOXO1 and c-Myc in normal and human breast cancer cell lines.

3.2 Material and Methods
Reagents
All the reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless specified
otherwise. DMEM and Trypsin were purchased from Thermo Fisher Scientic (Waltham,
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MA). Primary antibodies including cortactin, Phospho-Cortactin (Tyr421), phosphorserine, p44/42 MAPK (Erk1/2), Phospho-p44/42 MAPK (Erk1/2), Akt, phospho-Akt and
GAPDH, secondary antibody like anti-rabbit IgG peroxidase-conjugated were used for
western blotting and they were all purchased from Cell Signaling Technology (Danvers,
MA). RIN1 antibody were purchased from Invitrogen (Carlsbad, CA). FOXO-1, C-myc,
ETS2 and HMGB2 primary antibodies were purchased Elabscience (Huston, TX). And
Lipofectamine® 2000 kit was purchased from Invitrogen (Carlsbad, CA).

Cell culture
The breast cancer cell lines MCF-7 and MDA-MB-231, normal breast epithelial MCF12A cell lines, Platinum A(Plat-A) packaging cells were purchased from ATCC (Manassas,
VA). And the cell culture conditions were described in chapter 2 material and methods part.

Construction of Recombinant pMX-puro retroviruses and cell lines
The cDNAs of GFP, RIN1 and their mutants were sub-cloned into the pMX-puro vector
as previously described (Barbieri et al., 2004). The method of transfection was described
in Chapter 2.

Lysate preparation, SDS-PAGE and Western blotting
Cell lysates, SDS-Page and Western blotting were carried out as essentially described
in Chapter 2
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Cell Proliferation Assay
Cell proliferation assays were carried out as essentially described in Chapter 2

RNA preparation and RT-PCR
Total RNA was extracted from normal and breast cancer cells using RNeasy Plus mini
kit (Qiagen) according to the manufacturer’s protocol. The purity and concentration were
tested by using a Spectrophotometer (GE Healthcare). The complementary DNA (cDNA)
was synthesized by using iScript cDNA synthesis kit (Biorad, Hercules, CA). The thermal
cycling conditions were as listed: 5 minutes at 25°C, 46°C for 20minutes following 1
minute in 95°C. Real time PCR was performed using the SsoAdvanced Universal SYBR
Green Supermix (Biorad) following the manufacturer’s instructions in CFX96™ RealTime PCR Detection System (Bio-Rad). The conditions of the reactions were as follows:
95°C for 30 seconds followed by 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds.
The final cycle was followed by initial 65°C increasing to 95°C, 0.5°C increasement at 5
seconds(Milstein et al., 2007). The primers sequences were listed as below: RIN1 5’
GGCAGCAGAGGAGTAGCTTGA and 5’-GCTTGCTGGCGCTAAAAGG; FOXO1 5’AGTCTGTCTGAGATAAGCAATC

and

5’-CAGTTAATGATGTTGGTGATGAG;

GAPDH 5’-CTCTGGTAAAGTGGATATTGT and 5’-GGTGGAATCATATTGGAACA.

Telomerase Activity Assay
Transfected cells (1 × 105) were serum starved for 24 hours on a 12-well plate in the
incubator for 24 hours. After that, 100 ng/ml EGF was added to the sample well and
cultured for another 24 hours. The samples were collected and prepared following
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TPAPeze Telomerase detection kit instructions. The qPCR master mix contained the
following reagents: 10X TRAP reaction buffer, 50X DNTP mix, TS primer, TRAP primer
mix, Taq polymerase, EvaGreen dye and ddH2O. Then samples were amplified and
quantified by qPCR to quantified telomerase activity. The qPCR amplification protocol
was listed as below: Initial incubation at 30°C for 30 minutes, and then 95°C for 2 minutes.
Followed by 40 cycles of 94°C for 15 seconds, 59°C for 30 seconds and 72°C for 1
minute(Mender & Shay, 2015).

Statistical analysis
All experiments were carried out in triplicate and repeated at least three times. All error
bars represent the mean ± SEM and statistical significance was performed by two-tailed
student’s t test. *P<0.05 was considered statistically significant.

3.3 Results
3.3.1 Expression of RIN1 is decreased in breast cancer cell lines.
In order to investigate whether RIN1 has been altered in breast cancers, MDA-MB-231
and MCF-7 was detected comparing with normal epithelial breast cell line (MCF-12A).
First, RIN1 and GAPDH primers were designed and used for the real time PCR. Expression
of RIN1 in mRNA level from MCF-7 and MDA-MB-231 cell lines were quantified by RTPCR and compared to MCF-12A cells. The results depicted the transcript level of RIN1
reduced in breast cancer cell lines by comparison with MCF-12A cells (Figure 3.1a).
Furthermore, MCF-7 cells had lower expression of RIN1 in mRNA level. Next, the protein
level of RIN1 was analyzed by western blot. The results were consistent with RT-PCR
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results (Figure 3.1b). RIN1 protein expression in MDA-MB-231 and MCF-7 was
decreased, the amount of RIN1 protein was less than MCF-12A cells, indicating that loss
of RIN1 in cells may cause malignance of breast epithelial cells.
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Figure 3.1. Expression of RIN1 is decreased in breast cancer cell lines. A) Real time
PCR quantification of RIN1 message level in MCF-12A, MCF-7 and MDA-MB-231 cells.
B) Western blot for RIN1 protein expression on normal and metastatic epithelial breast cell
lines. Quantification data were analyzed relating to western blot results. Error bars
represent the mean ± S.E.M from more than three individual experiments. ***P<0.001 was
reported using two-tailed t-test.
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3.3.2 RIN1 inhibits cell proliferation in normal and metastatic epithelial breast cell
lines upon serum stimulation.
Cell proliferation is a critical risk factor in cancer cells (Farber, 1995). Additionally.
Uncontrolled cell proliferation has been defined as a trait for cancer cells (Lopez-Saez et
al., 1998). To study the effect of RIN1 on cell proliferation, RIN1 and GFP was transfected
into MCF-12A, MCF-7 and MDA-MB-231 cells. The results of MTT assay established
RIN1 suppressed cell proliferation in normal and metastatic epithelial breast cell lines
(Figure 3.2).
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Figure 3.2. RIN1 inhibits cell proliferation in normal and metastatic epithelial breast
cell lines upon serum stimulation. Cell expression GFP and RIN1 were incubated in the
96-well plate supplemented with 10% FBS in triplicate for 24 hours. 10ul of 5mg/ml MTT
solution was added to the plate, following incubation for another 4 hours. The absorbance
was measured at 490nm in plate reader. A) MCF-12A, B) MCF-7, C) MDA-MB-231. Error
bars represent the mean ± S.E.M from more than three individual experiments. **P<0.01
and ***P<0.001 were reported using two-tailed t-test.
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3.3.3 RIN1 blocks cell proliferation in normal and metastatic epithelial breast cell
lines upon EGF stimulation.
To further examine the role of RIN1 played in different breast epithelial cell lines, GFP
and RIN1 overexpression cells were stimulated in the absence or in the presence of 50ng/ml
EGF for 24 hours. The results displayed that RIN1 had the ability to block the rate of cell
proliferation in MCF-12A, MCF-7 and MDA-MB-231 cells upon EGF driven (Figure 3.3).
Comparing with non-stimulation cells, the cells which incubated with EGF showed an
increased rate of cell proliferation. This phenomenon revealed that EGF enhanced the rate
of cell proliferation including normal and cancer cells.
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Figure 3.3. RIN1 blocks cell proliferation in normal and metastatic epithelial breast
cell lines upon EGF stimulation. Cell expression GFP and RIN1 were incubated in the
96-well plate with or without 50ng/ml EGF in triplicate for 24 hours. 5mg/ml MTT solution
was added to the plate, following incubation for another 4 hours. The absorbance was
measured at 490nm in plate reader. A) MCF-12A, B) MCF-7, C) MDA-MB-231. Error
bars represent the mean ± S.E.M from more than three individual experiments. **P<0.01
and ***P<0.001 were reported using two-tailed t-test.
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3.3.4 RIN1:C terminus region plays a critical role on proliferation in metastatic
epithelial breast cell line.
To elucidate which specific domain in RIN1 is demanded in inhibiting cell proliferation,
RIN1: N terminus, RIN1:C-terminus, RIN1:VPS9 (R4) and RIN1:RA(R5) were created
and overexpressed in MDA-MB-231 cells. Figure 3.4a depicted the strongest inhibitory
effect on cell proliferation was produced by RIN1: C. On the opposite, RIN1: N reversed
the effect of RIN1: WT on the cell proliferation. In addition to investigate which individual
domain in RIN1 is much more important for the suppressing the cell proliferation, RIN1:R4
and RIN1:R5 were tested. The results in figure 3.4b described that RIN1:R5 had the most
forceful effect on the inhibitory of cell proliferation.
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Figure 3.4. RIN1: C terminus region plays a critical role on proliferation in metastatic
epithelial breast cell line. MDA-MB-231 cells expression GFP, RIN1 and its different
domains were incubated in the 96-well plate supplemented with 10% FBS in triplicate for
24 hours. Cell proliferation rate was tested as described in material and methods part. A)
MDA-MB-231 cells overexpressed GFP, RIN1, RIN1: N terminus and RIN1: C terminus
B) MDA-MB-231 overexpressed GFP, RIN1, RIN1:VPS9 and RIN1:RA. Error bars
represent the mean ± S.E.M from more than three individual experiments. **P<0.01 and
***P<0.001 were reported using two-tailed t-test.
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3.3.5 Ovexpression RIN1 and its mutant in MDA-MB-231 cells.
Transfection of GFP and RIN1 into MDA-MB-231 using retroviruses system was
depicted in the material and methods part (Barbieri et al., 2004). GFP, RIN1, RIN1:R2 and
RIN1:R3 were transfected and cultured in the plat-A cells for 2 days, the supernatant was
then collected and transferred into MDA-MB-231 cells for another 2 days. Then the cells
were selected with 4ug/ml puromycin. Cell lysate was collected and immunoblotted with
anti-RIN1 antibody to verify the expression of RIN1. The data of western blot clearly
showed that RIN1 and its mutants has been successfully transfected into MDA-MB-231
cells.

R3

R2

RIN1 GFP
RIN1

GAPDH

Figure 3.5. Overexpression RIN1 and its mutant in MDA-MB-231 cells. PMX-GFP,
PMX-RIN1 and PMX-RIN1 mutants were transfected into MDA-MB-231 cells, then
selected with 4ug/ml puromycin. Protein extracts form cells were prepared as mentioned
above. The expression of RIN1 and GAPDH were tested by western blot using anti-RIN1
and anti-GAPDH antibodies.
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3.3.6 EGFR signaling in MDA-MB-231 cells overexpression RIN1 and its domains.
Previously studies had shown that EGFR signaling altered cell proliferation (Wee &
Wang, 2017; Yewale et al., 2013). To deeply understand RIN1 in cell signaling mechanism
driven by EGF, Ras-MAPK and AKT-PI3K-mTOR pathways were tested. It was
considered that RIN1 regulated the EGFR downstream signaling protein such as Erk and
Akt, thus, the activation of Erk and Akt was evaluated. The western blot showed that
overexpression RIN1 dramatically inhibited the phosphorylation of Erk as well as Akt
(Figure 3.6 a). The results suggesting RIN1 blocks Ras-MAPK and AKT-PI3K pathways
upon EGF stimulation. In order to gain a better understanding the role of RIN1 played in
the cell signaling pathway, RIN1 different domains was designed, overexpressed and
analyzed the function in cellular pathways regulated by EGF in MDA-MB-231 cells. The
observation showed that RIN1:R3 blocked the p-Erk expression significantly. The
observation of the inhibitory effect of RIN1: R3 in Ras pathway is consistence with the
results of suppression of cancer proliferation, indicating VPS9 domain and RA domain are
crucial for this inhibitory effect.
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Figure 3.6. EGFR signaling in MDA-MB-231 cells overexpression RIN1 and its
domains. A) GFP and RIN1 overexpressed MDA-MB0231 was stimulated using 100ng/ml
EGF, total cell lysates were collected as depicted in material and methods part. The proteins
were subjected into 10%SDS gel and blotted to PVDF membrane, following anti-Erk, antipErk, anti-Akt and anti-pAkt antibodies to detect. B) Overexpression of RIN1, RIN1:R2
and RIN1:R3 in MDA-MB-231 were lysed and immunoblotted with anti-Erk and anti-pErk,
antibodies as described above. Quantification data were shown associated with western
blot results. Error bars represent the mean ± S.E.M from more than three individual
experiments. **P<0.01 and ***P<0.001 were reported using two-tailed t-test.
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3.3.7 Overexpression RIN1 affects transcription factor expression in MDA-MB-231
cells.
Recent studies showed that some transcription factors like Foxo1, c-Myc were involved
in the progression of cancer cells and regulated by receptor tyrosine kinases(Gabay et al.,
2014; Wang et al., 2014). To figure out if RIN1 influenced the transcription factor
expression, GFP and RIN1 were overexpressed in MDA-MB-231 cells and stimulated by
100ng/ml EGF. Then the cell lysates were obtained and anti-FOXO1, anti-c-Myc and antiETS2 antibodies were used to analyze. Interestingly, there was an obvious increase in the
expression level of FOXO1, whereas c-Myc level was reduced in the RIN1 overexpression
cells. This discovery may provide a potential mechanism of RIN1 in cancer cell signaling.
Overexpression RIN1 will enhance the expression of FOXO1, and in turn inhibits PI3KAKT pathway, leading to suppress cancer cell proliferation.
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Figure 3.7. Overexpression RIN1 affects transcription factor expression in MDA-MB231 cells. Cells overexpression GFP and RIN1 were stimulated with or without 100ng/ml
EGF. Cell lysate were collected as described above. The total protein extracts were subset
into 10% SDS gel and immunoblotted using following antibody. A) FOXO1, B) c-Myc, C)
ETS-2. Quantification data were analyzed related with western blot results. Error bars
represent the mean ± S.E.M from more than three individual experiments. **P<0.01 and
***P<0.001 were reported using two-tailed t-test.
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3.3.8 EGFR signaling in MCF-7 cells overexpression RIN1.
Similarity to the MDA-MB-231 cells, overexpression RIN1 in MCF-7 cells showed the
suppression effect on the phosphorylation of Akt and Erk upon EGF stimulation as well as
serum driven. Taken together, our observations indicated that RIN1 has inhibitory effect
on the Ras-MAPK and AKT-PI3K pathways in both invasive and non-invasive breast cells.
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Figure 3.8. EGFR signaling in MCF-7 cells overexpression RIN1. A) GFP and RIN1
overexpression cells were incubated with or without 100ng/ml EGF. Cell lysates were
obtained as depicted in methods part and then analyzed by western blot using anti-Erk,
anti-pErk, anti-Akt, anti-pAkt, anti-GAPDH and anti-RIN1 antibodies to detect. B)
Overexpression of GFP and RIN1 in MCF-7 cells with 10% FBS stimulation were lysed
and immunoblotted with anti-Erk and anti-pErk, antibodies as described above.
Quantification data were shown corresponding to the western blot results. Error bars
represent the mean ± S.E.M from more than three individual experiments. *P<0.05 and
***P<0.001 were reported using two-tailed t-test.
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3.3.9 Effect of RIN1 on telomerase activity in MDA-MB-231 cells.
Some studies showed that cell proliferation was highly correlated with telomerase
activity (Greider, 1998; Khattar et al., 2016). MDA-MB-231 cells overexpressed RIN1 and
GFP were stimulated by 100ng/ml EGF and incubated for 24 hours. Trap assay was used
to evaluate telomerase activity as mentioned in the material and methods part. The results
indicated that overexpression RIN1 had a lower telomerase activity as shown by RT-PCR
quantification, suggesting RIN1 may have a role in inhibiting telomerase activity by
affecting several signaling molecules.
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Figure 3.9. Effect of RIN1 on telomerase activity in MDA-MB-231 cells. GFP and RIN1
were overexpressed in MDA-MB-231 cells and stimulated with or without 100ng/ml EGF.
Expression of telomerase activity was analyzed by TRAP assay as mentioned in the
Material and Methods section. Error bars represent the mean ± S.E.M from more than three
individual experiments.
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3.4 Discussion
Epithelial growth factor receptor has been demonstrated that is usually upregulated in
multiple types of cancers involving breast cancer, glioblastoma, and colorectal cancer
(Arteaga, 2002; Sahin & Oktay, 2013; Xu et al., 2017). EGF binds with EGFR, and in turn,
EGFR will be dimerized and then autophosporylated. After that, adaptors will be recruited
and thus activate the downstream cell signaling pathways (Wee & Wang, 2017). The RasRaf-Mek-Erk and PI3K-AKT-mTOR pathway are the most critical signaling cascades in
mediating the EGFR induced biological activities, including cell proliferation, invasion,
and migration (Dibble & Cantley, 2015; Lewis et al., 1998; Morrison, 2012).
Cancer has been defined as a disease characterized by an increase in cell growth,
cellular motility and the acquisition of unlimited survival capacities in mutated cells
(Gutschner & Diederichs, 2012; Lopez-Saez et al., 1998; Porther & Barbieri, 2015). In
non-cancer cells, genome integrity and chromosomes stability are maintained by telomeres
(Jafri et al., 2016). Increasing evidence indicates that the length of telomeres is highly
regulated by telomerase (Shay & Wright, 2011). In normal cell lines, the expression of
telomerase is barely to observe. On the contrary, elevated level of telomerase is commonly
detected in human cancers (Shay & Wright, 2011). Telomerase affects cell senescence and
tumorigenesis by regulating cell division and the stability of the genome (Zhou et al., 2014).
A large amount of studies has been shown that telomerase activity correlates with the
malignancy of cancer cells (Boscolo-Rizzo et al., 2016; Gunes et al., 2018; Miyazaki et al.,
2015). Thus, telomerase activity plays a crucial role in cancer cells proliferation progress.
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To reach a better insight of telomerase activity, the transcription factor of telomerases
should be investigated. hTERT, an essential catalytic subunit of telomerase, comprises of
several binding sites for multiple transcription factors such as ETS2 and c-Myc (Wang et
al., 1998; Xu et al., 2008; Zhao et al., 2014). It has been clearly shown Myc plays as an
oncogene in cancer progression (Koh et al., 2015). The major effects of c-Myc on cancer
characteristics contain abundant biological functions, including cell proliferation,
migration, and cell survival (Xu et al., 2008). Interestingly, blocking PI3K-Akt pathways
inhibits Myc translation (Chen et al., 2018). ETS, the other promoter of hTERT, is a family
containing many members and have a contribution to the telomerase. Especially, ETS2 is
a crucial promoter for hTERT expression leading to cancer cell proliferation (Fry & Inoue,
2018). Furthermore, ETS2 interacts with c-Myc, and both of them regulates the expression
of hTERT. ETS2 has been reported to inhibit can cell migration in lung cancer cells and
suppress the Ras-Raf-Erk pathways (Hsu et al., 2015).
Forkhead box O(FOXO) transcription factors acts a vital regulator in response to
biological activities such as apoptosis, stress, DNA damage/repair, tumorigenesis,
angiogenesis, and glucose metabolism (Zhang et al., 2011). FOXO1 has been defined as a
tumor suppressor which can be explained from different molecular points (Farhan et al.,
2017). First, it can promote the expression of variety pro-apoptotic members of the Bcl2
family, and also stimulate the expression of death receptor ligands such as Fas ligand
(Morris et al., 2005). Second, FOXOs have the effect on augment expression levels of
several cyclin-dependent kinase inhibitors (CDKI) (Yuan et al., 2008). Finally, combined
with its function to crosstalk with p53, another tumor suppressor, FOXOs show its clear
inhibition effect on cancer cells (You & Mak, 2005).
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Additionally, FOXO1 is phosphorylated by PI3K- Akt signaling pathways with IGF or
EGF stimulation, resulting in translocation from the cell nucleus to cytoplasm, which leads
to inactivation of transcriptional activity, thereby inhibiting downstream gene expression
regulated by FOXO1 (Cabodi et al., 2009; Ding et al., 2014).
In my study, overexpression RIN1 in MDA-MB-231 cells showed an inhibitory effect
on cell proliferation with either serum-induced or EGF stimulated comparing to the control
cell. Then the individual domains were transfected and detected. Not surprisingly, RIN1:
R5 had the most forceful suppression effect on cell proliferation, indicating RA domain
has an essential role in the cancer characteristics, including cell proliferation, migration,
and invasion (Described in chapter 2). Then the cell signaling pathways, consisting of
PI3K-Akt and Ras-Raf-Erk, were detected upon EGF stimulation in metastatic and nonmetastatic breast cancer cell lines. Phosphor-Erk and phosphor-Akt were inhibited
dramatically in MDA-MB-231 cells as well as MCF-7 cells, suggesting that RIN1 blocks
breast cancer cell proliferation by suppressing PI3K-Akt and Ras-Raf-Erk pathways.
Furthermore, RIN1: R3 showed a much stronger ability to attenuate the expression of
phosphor-Erk comparison to RIN1: WT cells. The results are consistence with cell
proliferation results.
To gain a better knowledge of mechanism of RIN1 inhibition in cell proliferation, trap
assay was carried out to test the telomerase activity. The results represented that
overexpression RIN1 had a lower activity compared to GFP cells in MDA-MB-231 cells.
The promoter of hTERT, including ETS2 and c-Myc were detected. The data revealed that
the level of ETS2 was increased, whereas c-Myc decreased in RIN1 overexpression cells.

109

This finding supports the hypothesis that RIN1 regulates telomerase activity by inhibition
of the expression of the promoter.
Finally, the level of FOXO1 was also evaluated in MDA-MB-231 cells. The results
described that overexpression RIN1 enhanced the expression of FOXO1, suggestion
another role of RIN1 played in the cell signaling cascade. RIN1 may interact with FOXO1,
and this complex inhibits Akt phosphorylation and c-Myc translation. Taken together, the
data represent a novel role of RIN1 on several downstream signaling in the EGF driven
and it is associated with telomerase activity.
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CHAPTER 4
EFFECT OF RIN1 ON CELL PROLIFERATION, MIGRATION AND
INVASION IN SEVERAL CANCER CELL LINES
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4.1 Introduction
Recent studies have pointed out that small GTPases have recently become important
molecules in molecular and cell biology and are important regulators of multiple
cellular processes such as cell proliferation, cell motility and cell cytoskeleton
organization (Carvalho et al., 2015). Small GTPases contain a numerous different type
of proteins varying from the monomeric and heterotrimeric G proteins (Csepanyi-Komi
et al., 2012). These small GTPases plays an important role in the process of controlling
a variety of biological functions, especially in signal transduction, cell migration,
invasion and colony formation.

The Ras superfamily, which belongs to the small GTPase, is the most widely studied
and may have the best understanding of cell function. The Ras gene was found to be an
oncogene in the Kirsten Rat sarcoma virus (KRas) (Tsuchida et al., 1982), leading to
the identification of other small GTPases with similar structures to Ras. The Ras
superfamily can be defined as many groups: Ras, Rho, Rab, Arf and Ran (Carvalho et
al., 2015). Each group in the Ras superfamily has a similar molecular size, protein
structure, and their enzymatic activity is regulated by GEFs and GAPs (Bos et al., 2007;
Hennig et al., 2015; Wennerberg et al., 2005).

Cellularly, these small GTPases are primarily involved in several intracellular
signal transduction pathways and regulate cell proliferation (Simanshu et al., 2017).
Some of them (ie, Rho proteins) rearrangement cell cytoskeleton and plays a vital role

119

in cell motility, the others (i.e., Arf and Rab proteins) are reported to involve in the
vesicle formation and trafficking (Bos et al., 2007). Structurally, all Ras superfamily
share a highly conserved guanine nucleotide binding domain (Cherfils & Zeghouf, 2013)
with two switch regions referred to as Switch 1 (residues 8 amino acids) and Switch 2
(17 amino acids). These switches suffer conformation when GDP or GTP is loaded to
the protein (Carvalho et al., 2015). Also, the carboxy terminus is highly variable and is
post-translated modified by the attachment of farnesyl or geranylgeranyl motives that
is essential for its function (Bos et al., 2007).
Activation of Ras mostly associates with numerous growth factors such as EGF,
INS or IGF-1 binding to their specific receptors. When the RTKs get phosphorylated,
it will encourage the adaptor such as SOS to bind with GEF like Grb2 and then the Ras
can be activated. This step will allow Ras from GDP form to GTP activation (Erijman
& Shifman, 2016). The other small GTPases like Rab5 small GTPase there are, so far,
10 GEF proteins with such activities and they have in common that all of them contain
the Vps9 domain (Hadano et al., 2004; Hermle et al., 2018; Ishida et al., 2016; Kajiho
et al., 2012; Kajiho et al., 2003; Kimura et al., 2006; Marichal et al., 2016; Otomo et
al., 2003; Tall et al., 2001; Tamura et al., 2009). The most famous Rab5 GEF is RIN1,
some studies showed RIN1 activated Rab5 through VPS9 domain by inserting the
specific residue (i.e., aspartate residue) into the nucleotide binding site (Barr &
Lambright, 2010).
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Interestingly, a mounting body of data point out that tumor cells are associated with
small GTPases (McFarlin et al., 2003). Metastasis is the most important hallmarks in
cancer cells. Cancer cells need to acquire high cell motility to lead to cell invasion,
which are associated with numerous changes in morphology (i.e., cell polarity) that is
also supplement by increased cell motility. The Rho small GTPases highly regulate
cytoskeletal dynamics (Jansen et al., 2018).
Surprisingly, the Ras small GTPases isoforms are often accompanied by high
frequency mutations in most human cancers. Among them, the three major isoforms of
Ras (K-Ras, N-Ras and H-Ras) have 10% to 35% mutations in numerous cancers (Alan
& Lundquist, 2013). Mutation of Ras always happens at positions 12, 13, and 61.
Besides, the mutations have the effect on interfering the interaction of RasGAP with
RAS activated form to hydrolyze GTP (Simanshu et al., 2017).
In addition, the mutated RasGAP loses its original function and significantly
promotes tumor development. For example, in glioblastoma, a RasGAP has been
discovered to be lost. This phenomenon is common and leads to the development of
type 1 neurofibromatosis (Vigil et al., 2010). Recently, it has been determined that
epigenetic regulation of RasGAP is an important mechanism for tumor formation and
progression of prostate cancer, breast cancer and hepatocellular carcinoma (Calvisi et
al., 2011; Maertens & Cichowski, 2014; McLaughlin et al., 2013).
In general, the Ras superfamily of small GTPases mediates many critical cellular
processes involved in cell invasion and proliferation. Abundant studies have shown that
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mutations of small GTPases are common observed in different types of cancer cells. In
this chapter, we investigated what is the effect of the expression of Rin1, a Rab5 GEFs,
on three key hallmark capabilities (i.e., proliferation, invasion and colony formation)
on human glioblastoma and human melanoma cell lines in order to determine where
this effect is cell type specific.

4.2 Materials and Methods
Reagents
All reagents have been described in Chapter 2 under Material and methods section.

Cell culture
The brain cancer cell line including U118MG and U87 MG, Skin cancer line-Yusik
cells and Platinum A(Plat-A) packaging cells were obtained from ATCC (Manassas,
VA). The U118MG, U87 MG and HEK- 293T cells were cultured in DMEM with 10%
FBS, 2 mM glutamine, penicillin and streptomycin. Plat A cells were grown in DMEM
with 10% FBS, 100 unit/ml penicillin and 100 ug/ml streptomycin, 1ug/ml puromycin
and 10ug/ml blasticidin. Yusik cells were cultured in the Opti-Mem media
supplemented with 5% FBS. All the cells were incubated at 37°C with 5% CO2 in
humid surroundings.
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Construction of Recombinant pMX-puro retroviruses and cell lines
The cDNAs of RIN1 were sub-cloned into the pMX-puro vector as previously
described (Barbieri et al., 2004). When the Plat-A cells reaches 80% confluent, DNA
was transfected with lipofectamine 2000 kit and harvested for 48 hours. The supernatant
containing retrovirus were collected and filtered through 0.45 uM filter, and then added
with polybrene to the target cells for 48 hours. Then 1 to 2ug/ml puromycin was used
to select cells for 3 days.

Lysate preparation, SDS-PAGE and Western blotting
This part of the experiemtnal approach has been already described in chapter 2
under Material and Methods section.

Cell Proliferation Assay, Wound healing assay, Transwell invasion assays, Soft agar
colony formation assay and Statistical analysis
This part of the experiemtnal approach has been already described in chapter 2
under Material and Methods section.
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4.3 Results
4.3.1 RIN1 expression is elevated in U87 cells.
From now on, very few studies mentioned the role of RIN1 in glioblastoma cell
lines, thus, it is vital to know the function of RIN1 in brain cancer cells. First, we
compared the RIN1 protein expression level in U87 and U118 cells lines. The results
represented in U118 cells, RIN1 had lower protein expression in comparison to U87
cells

U87

RIN1 expression in glioma cell
line
RIN1

GAPDH

RIN1 protein expression level

U118

1.2
1
0.8
0.6
0.4
0.2
0
U87

U118

Figure 4.1. RIN1 expression is elevated in U87 cells. Western blot for RIN1 protein
expression on glioblastoma cell lines. Quantification data were analyzed relating to
western blot results. Error bars represent the mean ± S.E.M. from more than three
individual experiments.
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4.3.2 RIN1 inhibits cell proliferation in U118 cells.
Since cell proliferation was inhibited in breast cancer cells with overepression Rab5
GEF, the effect of RIN1 in glioblastoma should be elucidated. Thus, PMX-GFP and
PMX-RIN1 vectors were transfected to the U118 MG cells using retrovirus system.
U118 cells stable overexpressed RIN1 was seeded into 96 well plate ,incubating with
10%FBS and the cell proliferative activity was mesured based on the MTT assay. The
results was similar to the breast cancer cells, overexpresson RIN1 inhibits cell
proliferation (Figure 4.2).

MTT assay
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Figure 4.2. RIN1 inhibits cell proliferation in U118 cells. Cell expression GFP and
RIN1 were incubated in the 96-well plate supplemented with 10% FBS in triplicate for
24 hours. 10ul of 5mg/ml MTT solution was added to each well, following incubation
for 4 hours. The absorbance was measured at 490nm in plate reader. Error bars represent
the mean ± S.E.M from more than three individual experiments. **P<0.01 was reported
using two-tailed t-test.
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4.3.3 RIN1 inhibits cell migration and invasion in U118 cells.
Cell migratin and invasion are the hallmarks of cacer, it is necessary to know if
RIN1 affetcs the brain cancer cell charasteristics. Stable cells overexpression RIN1 and
GFP were plated for the migration and transwell insert invasion assay as described in
material and methods in chapter 2. We found overexpression RIN1 supresses the cancer
migration and invasion in U118 cells.
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Figure 4.3. RIN1 inhibits cell migration and invasion in U118 cells. Brain cancer
cells overexpressed GFP and RIN1 were incubated until reaching 80% confluence. A)
Migration assay for 18 hours in 10% FBS. B) Cell expression either GFP and RIN1
were seeded in the transwell insert and incubate for 24 hours with 10%FBS in the
bottom well. The quantification data were analyzed associated with cell invasion results.
Error bars represent the mean ± S.E.M from more than three individual experiments.
***P<0.001 was reported using two-tailed t-test.
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4.3.4 Tumor formation is inhibited with RIN1 overexpression in U118 cells.
In the progression of cancer, the ability of transformed cells to grow independently
can be treated as a marker for metastasis (Borowicz et al., 2014; Mori et al.,
2009).Combination of the proliferation, migration and invasion results, RIN1 had the
ability to inhibit the cell migration and invasion. It was crucial to find the RIN1
influences on the ability of colony formation in U118 cells. The results pointed out that
RIN1 overexpression decreased not only the size, but the number of colonies compared
with control in U118 cells (Figure 4.4).
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Figure 4.4. Tumor formation is inhibited with RIN1 overexpression in U118 cells.
Brain cancer cell lines were plated in the layer of 0.35% agarose, cells were allowed to
grow at 37℃. 100ul of 10% FBS growth media was added to the well every 2-3 days.
After 15 days, the colonies were stained with 0.01% crystal violet and photographed
under low magnification. The quantification data were analyzed associated with cell
colony formation results. Error bars represent the mean ± S.E.M from more than three
individual experiments. ***P<0.001 was reported using two-tailed t-test.

128

4.2.5 RIN1-C terminus inhibits the expression of phosphor-Erk in U118 cells.
In order to deeply understand the mechanism of RIN1 in cell signaling, RasMAPK pathway was tested. The data showed that overexpression RIN1 inhibited the
phosphorylation of Erk significantly (Figure 4.5). The results suggesting RIN1 blocks
Ras-Raf-Erk oncogenic pathways. To have a deep understanding of the role of RIN1
played in the cell signaling pathway, RIN1 different domains was designed,
overexpressed and analyzed the function in cellular pathways in U118 cells. The
observation indicated that RIN1:R3 blocked the p-Erk expression significantly,
suggesting RA domain in RIN1 is vital for this inhibitory effect.
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Figure 4.5. RIN1-C terminus inhibits the expression of phosphor-Erk in U118 cells.
Overexpression of GFP, RIN1 and its domains in U118MG cells with 10% FBS
stimulation were lysed and immunoblotted with anti-Erk and anti-pErk, antibodies as
described above. Quantification data were shown corresponding to the western blot
results. Error bars represent the mean ± S.E.M from more than three individual
experiments. ***P<0.001 was reported using two-tailed t-test.
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4.2.6 RIN1 facilitates cell proliferation in U87 cells.
In U118 cells, RIN1 showed inhibitory effect and we want to find if it shows same
infuence on the U87 cells. U87 cells expressed GFP and RIN1 were plated and
incubated as depicted in material and methods parts in chapter2. Interstingly, cells
overexpressed RIN1 showed an opposite effect on the U87 to U118 cells. Cell showed
a intense increase in cell proliferation with overexpression RIN1.
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Figure 4.6. RIN1 facilitates cell proliferation in U87 cells. Cell expression GFP and
RIN1 were incubated in the 96-well plate containing 10% FBS in triplicate for 24 hours.
10ul of 5mg/ml MTT solution was added to each well and let it react for additional 4
hours. The absorbance was measured at 490nm in plate reader. Error bars represent the
mean ± S.E.M from more than three individual experiments. **P<0.01 was reported
using two-tailed t-test.
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4.2.7 RIN1 suppresses cell migration and invasion in U87 cells.
Cell migration and invasion were measured using wound healing assay and
trasnwell insert invasion assay. In figure 4.7a, cell overexpressed RIN1 showed high
gorwth rate and formed the multilayer spheroids when they reached the high density.
In figure 4.7a and 4.7b, there was a significant increase in the migration and invasion
effect on the U87 cells. Therefore, RIN1 exhibits the role on the invasive and migratory
poteintial in U87 cells.
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Figure 4.7. RIN1 suppresses cell migration and invasion in U87 cells. A)
Morphology of U87 cells overexpressed GFP and RIN1. B) U87MG cells
overexpressing GFP and Rin1: WT were seeded into transwell insert as described in
Material and Methods. The invaded cells were counted after 18 hours. The
quantification data were analyzed associated with cell invasion results. C) Cell
overexpressed GFP and Rin1: WT were plated into 12-well plate, cell free areas were
created and induced by 10% FBS for 24hours. The scratch edge was measured and
calculated. The quantification data were analyzed related with cell migration results.
Error bars represent the mean ± S.E.M from more than three individual experiments.
***P<0.001 was reported using two-tailed t-test.
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4.2.8 Effect of RIN1 on tumor formation in U87 cells.
Prior data showed RIN1 promoted cell migration and invasion. To have a better
understanding of RIN1 influences on U87 cells characteristics, it was necessary to
discover the RIN1 effect on the ability of colony formation in U87 cells. The results
showed that RIN1 overexpression increased not only the size, but the number of
colonies compared with control in U87 cells (Figure 4.8).
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Figure 4.8. Effect of RIN1 on tumor formation in brain cancer cells. U87MG cells
expressed GFP and RIN1 were plating in low concentration of agarose layer and
cultures for 15 days with 10% FBS stimulation. Colonies were stained using 0.01%
crystal violet, then the pictures were taken and calculated each well. The quantification
data were analyzed corresponding to cell colony formation results. Error bars represent
the mean ± S.E.M from more than three individual experiments. ***P<0.001 was
reported using two-tailed t-test.
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4.2.9 Cell signaling in U87 cells with RIN1 overexpression.
To gain a better understating why RIN1 showed a reverse effect on U87 cells,
oncogenic Ras-MAPK pathways was tested. We found that overexpression RIN1
enhanced the phosphorylation of Erk significantly (Figure 4.5). The results suggested
RIN1 lost the binding ability with Rad and thus could not compete with Raf.
Furthermore, we tested the phosphorylated tyrosine cortactin which was commonly
involved in aggressive cancer. Prior data have shown RIN1 interacts with cortactin and
inhibits the phosphorylation of cortactin. Interestingly, in U87 cells, overexpression
RIN1 facilitates the phosphorylation of cortactin dramatically. Overall, these
observations provide two mechanisms of RIN1 exhibits oncogenic properties: 1. Loss
the ability to interact with Ras and cannot block Ras-Raf-Erk pathway, and 2.
Interaction with cortactin and thus uptake the phosphorylation cortactin level.
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Figure 4.9. Cell signaling in U87 cells with RIN1 overexpression. Overexpression of
GFP and RIN1 in U87MG cells with 10% FBS stimulation were lysed and
immunoblotted with A) anti-Erk and anti-pErk, B) anti-cortactin and anti-phophotyrosine cortactin (Tyr421) antibodies as described above. Quantification data were
shown corresponding to the western blot results. Error bars represent the mean ± S.E.M
from more than three individual experiments. ***P<0.001 was reported using twotailed t-test.
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4.2.10 Overexpression RIN1 promotes call proliferation and migration in Yusik
cells.
RIN1 showed the opposite function in diverse type of cancers, what is the role of
RIN1 in Yusik cells? We transfected GFP and RIN1 constructs into Yusik cells and
measured the cell proliferation and migration as described in the material and methods
part in chapter 2. We found that RIN1 acted an non-tumor suppressor by faciliating cell
proliferation and migration (Figure 4.10).
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Figure 4.10. Overexpression RIN1 promotes call proliferation and migration in
Yusik cells. A) Cell expression GFP and RIN1 in Yusik cells were incubated in the 96well plate containing 10% FBS in triplicate in the incubator for 24 hours. Cell
proliferation was followed the protocol as mentioned in material and methods section
B) Overexpressed GFP and RIN1 cells were allowed to migrate 24 hours, the pictures
were taken and analyzed. Error bars represent the mean ± S.E.M from more than three
individual experiments. ***P<0.001 was reported using two-tailed t-test.
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4.4 Discussion
Ras interference 1(RIN1), a multifunctional protein, has SH2 and Proline rich
domain in the N terminus, VPS9 and RA domains in the C terminus. Increasing
evidence show that RIN1 could be a critical intracellular factor linking RTK activation
with cell survival. Previous studies have shown that RIN1 played a different role in
different types of cancers.
In breast cancer, RIN1 acts like tumor suppressor, whereas in non-small cell lung
adenocarcinoma cell lines, overexpression RIN1 promotes cell proliferation (Tomshine
et al., 2009). The explanation of RIN1 function in enhancing the cell proliferation can
be explained RIN1 mediates EGFR signaling pathway which is regulated by
internalization and endocytic trafficking. The other group reported the relationship
between RIN1 overexpression and the rate of patients’ survival. The results indicated
that RIN1 up-regulation related to poor prognosis of NSCLC patients (Wang et al.,
2012). Similarity effect of RIN1 in breast cancer cells, Overexpression RIN1 led to the
cell migration inhibition. And the expression of RIN1 was downregulated in patients’
samples (He et al., 2013). In gastric cancer, bladder urothelial carcinoma and colorectal
cancer, all of them were reported overexpression with RIN1 associated with poor
prognosis in patients (Senda et al., 2007; Shan et al., 2012; Yu et al., 2012). The study
of RIN1 with colorectal cancers pointed out that the potential mechanism of the RIN1
oncogenic function could be explained by the location of RIN1 in cells. In colorectal
cancer cells, RIN1 located majority in cytoplasm instead of the cell membrane, thereby
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lost the ability to compete with Raf and inhibited Ras-Raf-Erk pathway.
Glioblastoma is one of the most aggressive primary brain tumors associating with
low patients’ survival (Kutwin et al., 2017). There was no study with RIN1 expression
and brain cancer before, therefore, it is important to know the role of RIN1 in
glioblastomas. We overexpressed GFP and RIN1 in U118 and U87 cells, surprisingly
we found RIN1 had totally opposite effect on both cell lines. Like in U87 cells lines,
overexpressed RIN1 facilitated cell migration, invasion and ability to form the colonies.
On contrast, the inhibitory effect was shown by RIN1 in U118 cells. Previous studies
discovered RIN1 was naturally deleted 62amino acid whereas U87 did not (Han et al.,
1997). We tested the Ras-Raf-Erk pathway, it showed that overexpression RIN1,
especially RIN1:R3 inhibited the phosphor-Erk expression. In U87, it reserved the
effect on the inhibition of Ras-Raf-Erk pathway. Interestingly, we tested the
phosphorylated cortactin expression, the results showed that overexpression RIN1
promoted the level of phosphorylated cortactin. It could be explained that RIN1
interacts with cortactin but loses its inhibition activity on phosphorylated cortactin.
Fang et al. showed RIN1 acts oncogenic property in melanoma cell line: A375 cells.
RIN1 silenced in this cell lines inhibited cell proliferation and induced the cell apoptosis.
In my study, I choose the Yusik cell lines, which is human B-Raf (V600E) mutation cell
lines, to test the RIN1 function. The results were consistence with previously studies,
RIN1 was not a tumor suppressor in Yusik cells. Overexpressed RIN1 lead to
enhancement of cell proliferation and migration. It has been showed that BRAF mutant
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was Ras-independent and gained abundant increasement of activation (Yao et al., 2015).
Interestingly, in Yusik cells which carried the B-Raf mutation, we did not see
suppression effect on the cell with RIN1 overexpression. It can be explained in
melanoma cells, RIN1 loses its ability to bind with Ras and compete with Raf.
Overall, there are still some unclear functions of RIN1 in many different types of
cancers. Thus, moving forward, we should elucidate the mechanisms of RIN1 from the
cellular and molecular points, focusing on intracellular signaling cascade driven by
growth factor.
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CHAPTER 5
CONCLUSIONS AND FUTURE WORK
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Cortactin is a multi-domain protein involved in the regualtion of actin. It is enriched
at membrane ruffles as well as lamelliopadia in all cell types together with actin and
other adaptor proteins. Additionally, it has been reported to have a crucial effect many
intracellular processes, involving cell migration and invasion, axon guidance and
neuronal morphogenesis. Moreover, cortactin has been shown overexpressed in various
tumor cells leading to metastasis. In fact, regulation of cortactin by phosphorylation is
a vital mechanism by which numerous cancer cells obtain more aggressive behavior
which is common related with malignant transformation.

RIN1 may be able to negatively control cortactin function in cancer cells setting its
capability to regulate signaling through both Ras/PI3K/Akt and Ras/MAPK pathways,
respectively as well as by sequestering cortactin and therefore, inhibiting its
intracellular activity. Competing with Raf binding to the Ras via its RA domain strongly
trusted to result in attenuation of Erk phosphorylation. Similarly, the Akt inhibition is
being observed by the inhibition of the interaction between Ras and PI-3 kinase. This
hypothesis was assessed in breast cancer cell lines overexpressing RIN1 and its mutants
as well as Cortactin constructs. Three specific aims were established to examine the
cellular and molecular mechanism by which RIN1 regulates invasion, migration and
colony formation.

The first aim discovered a new interacting partner for RIN1 and in indeed a novel
cellular mechanism by RIN1 blocks cell migration and invasion as well as colony
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formation. It points out the importance of the cellular importance of proline rich domain
of RIN1on cellular migration and invasion in both normal and metastatic epithelial
breast cancer cells. These cell lines include metastatic and highly invasive MDA-MB
231 breast cancer cells, tumorigenic but non-invasive MCF7 breast cancer cells, and as
normal cells we utilized a non-tumorigenic MCF12A breast epithelial cells.
RIN1 apparently works with a dual activity in this cell type: First, it sequesters
cortactin and thus, this interaction with the proline rich of RIN1 blocks the cellular
function of cortactin to promote cellular migration and invasion. Second, RIN1
interacts with the activated Ras via the Ras association (RA) domain and decreased
both tyrosine and serine phosphorylation of RIN1. This inhibitory effect on
phosphorylation of cortactin producing by RIN1 may be due since the interaction of
Ras, which blocks both Erk and Akt activities upon EGF stimulation. The suppression
of cell migration was also found in MCF-7 cells as well as non-tumorigenic MCF-12A
cells. This phenomenon may be partly elucidated that MDA-MB-231 cells show an
unusual activity for Ras small GTPase. In fact, a Ras: G12V mutant, which is a mutant
caused constitutively active form of Ras that might affect somehow the inhibitory effect
of RIN1. Receptor kinase receptors consisting of the IGF-1R and EGFR play a
prominent role in breast cancer progression. The function of EGF and IGF in cancer
cell migration, invasion, and proliferation have well established. Several abnormalities
on activities and expression in these receptors very often provide uncontrolled cell
proliferation, which is one of the more critical characteristics of several types of cancers.
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The second aim examined the effect of the expression of RIN1: WT and several
RIN1 mutants constructs on several signaling transduction molecules in MDA-MB 231
cells. Western blotting analysis of critical signaling proteins downstream of the active
form of Ras following EGF stimulation reveals RIN1 inhibits cell proliferation through
Ras-Raf -Erk and PI3K-AKT signaling cascades in breast cancer cells. The RA domain
in RIN1 has the strongest ability to inhibit cancer cell characteristics including cell
migration, invasion and proliferation. Moreover, it is interesting to find that
overexpression of RIN1 elevated the expression of FOXO1 which is a tumor suppressor
in breast cancer cells. On contratry, expression of c-Myc was inhibited. Both FOXO1
and c-Myc are transcription factors involved in cancer cell progress, FOXO1 showed
the inhibitory effect on the P13K-AKT and thus inhibits cell proliferation. However, cMyc overexpression has been found in various types of cancer cells, leading to an
increase in the cellular growth. Telomerase activity was also detected in this study.
Cancer cells commonly show higher telomerase activity resulting to the uncontrolled
cell proliferation, overexpression RIN1 examined the inhibitory effect on the
telomerase activity upon EGF stimulation. This may be a potential mechanism to
explain the inhibitory effect that RIN1 had on cancer cell migration, invasion and
proliferation. Taken together, these data support RIN1 acts like tumor suppressor in
MDA-MB-231 breast cancer cells by regulating several transcription factors.
The third aim investigated the effect of RIN1 expression on migration, invasion and
colony formation in melanoma and glioblastomas cell lines. We chose the human
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melanoma cells (i.e., YUSIK) and human glioblastoma cells (i.e., U87 MG and U118
MG) to determine the effect of RIN1. In the YUSIK melanoma cells which has a mutant
form of BRAF where its activity does not depend on the activation of Ras. (i.e., RAF:
V600E), overexpression RIN1 enhanced cancer migration and proliferation. It revealed
a completely opposite role of RIN1 had on cancer migration and proliferation compared
to breast cancer cell lines. The potential explanation of this phenomenon is that in Yusik
cells, Raf was mutant and it showed the consecutive activity in Ras-Raf-Erk pathway
and enhanced cell proliferation. RIN1 at that time, loss the binding ability with Ras and
can’t block Ras-Raf-Erk pathway. The mechanism of RIN1 in melanoma cells remains
unclear, the further study should focus on that part.
In summary, this current research discovered a novel activity for RIN1 in metastatic
breast cancer cell lines. Specifically, RIN1 is able to interact with cortactin, and also to
suppress cortactin function as an enhancer of tumorigenic activity. Future experiments
should be carried out to elucidate the potential molecular mechanism of the tumor
suppressive role for RIN1 in breast cancers, and more important, this data indicate that
RIN1 could be utilized as tumor marker for breast cancer.

149

VITA
WEI ZHANG
2010-2014

Bachelor’s degree
Pharmacology
China Pharmaceutical University, Nanjing, Jiangsu, China

2014-2019

Graduate Teaching Assistant
Department of Chemistry and Biochemistry
Florida International University, Miami, Florida

PUBLICATIONS AND PRESENTATIONS
Huang, Y., Zhang, W., Veisaga, M.L., Barbieri, M.A., A single amino acid change in
Ras Interference 1 alters its function. Science Research Conference, Federation of
America Societies for Experimental Biology (FASEB) (U.S., 2016)
Y. Huang., W. Zhang., M.L. Veisaga., M.A. Barbieri., Selective effect of Rin1
mutants on insulin signaling during pre-adipocyte differentiation. American Society
for Cell Biology (ASCB) Annual Meeting (U.S., 2016)
Persaud, S., W. Zhang., Soriano, S., Veisaga, M.L., M.A. Barbieri., Anti-migration
and anti-attachment Activities of Natural Compounds from Genus Artemisia. Summer
Research Internship Mini-symposium Florida International University, Miami, FL
(U.S., 2017)
W. Zhang., M.A. Barbieri., New insight into the RIN1 function: Is cortactin a novel
RIN1-interacting partner in cancer cell invasion? Biology Research Symposium,
Florida International University, Miami, FL (U.S., 2018)
W. Zhang., M.A. Barbieri., Specific requirement for Ras interference 1 during cell
migration. American Society for Cell Biology (ASCB) Annual Meeting (U.S., 2018)
W. Zhang., M.A. Barbieri., RIN1 controls cell migration and invasion in breast cancer
cells. BSI Research Symposium, Florida International University, Miami, FL (US.,
2019)

150

Huang, Y, Zhang, W, Veisaga, ML, Nadar, VS, Rosen, BP and Barbieri, MA. (2016)
A single amino acid change in Ras Interference 1 alters its function. A single amino
acid change in Ras Interference 1 alters its function. Science Research Conference,
Federation of America Societies for Experimental Biology (FASEB).
Veisaga, ML, Zhang, W, Huang, Y, Nadar, VS, Rosen, BP and Barbieri, MA. (2019)
Selective amino acid changes in Ras Interference 1 alter its function. (Submitted)
Porther, N, Zhang, W, Veisaga, ML, and Barbieri, MA. (2019) IGF-1 drives
activation of Rab5 via Rin1 dysregulating proliferation and invasion of MCF-7 cells.
(In Preparation)
W. Zhang., M.A. Barbieri. (2019) Ras interference 1 selectively regulates cell
migration via Cortactin. (In Preparation)
W. Zhang., M.A. Barbieri. (2019) Ras interference 1-FOXO pathways in breast
cancer. (In Preparation)

151

